

**PROGRAMME
AND
ABSTRACTS**

Thorax


British Thoracic Society Winter Meeting 2009





The Queen Elizabeth II Conference Centre
Broad Sanctuary
Westminster
London SW1P 3EE

**2–4 December 2009
Programme and Abstracts**


Map to QEII Conference Centre

PowerPoint preview facilities will be available throughout the three days of the Meeting in the Thames Room on the first floor of the Centre. All presenters and chairs should report to the Speakers' section of the Registration Desks on arrival.




-  Parking facilities are available nearby, but are very limited.
-  The nearest tube stations are St James's Park and Westminster on the District and Circle Lines.
-  Bus routes 24, 11 and 511 all stop nearby.
-  Victoria Station is approximately 15 minutes' walk down Victoria Street from the Conference Centre.

QEII Conference Centre – Ground and First Floors




Full cafe facilities will be open from 8.00am to 4.00pm each day in the Pickwick Suite on the 1st floor. A snack bar, serving hot and cold drinks, sandwiches and confectionery only, will be open in the Whittle & Fleming Rooms on the 3rd floor, also from 8.00am to 4.00pm daily.

QEII Conference Centre – Second and Third Floors



Full cafe facilities will be open from 8.00am to 4.00pm each day in the Pickwick Suite on the 1st floor. A snack bar, serving hot and cold drinks, sandwiches and confectionery only, will be open in the Whittle & Fleming Rooms on the 3rd floor, also from 8.00am to 4.00pm daily.

QEII Conference Centre – Fourth, Fifth and Sixth Floors



Full cafe facilities will be open from 8.00am to 4.00pm each day in the Pickwick Suite on the 1st floor. A snack bar, serving hot and cold drinks, sandwiches and confectionery only, will be open in the Whittle & Fleming Rooms on the 3rd floor, also from 8.00am to 4.00pm daily.

PROGRAMME at a glance**WEDNESDAY 2 DECEMBER 2009**

Time	Details	Location/Floor	
8.00am – 9.00am	COFFEE/TEA	Whittle & Fleming Rooms/3 rd	
8.45am – 4.00pm	Poster viewing	PI–P12 NIV in clinical practice: views from the front line P13–P27 Lung cancer: what's new in diagnostics and therapies P28–P34 Clinical observations in pulmonary vascular disease P35–P50 Delivering services in the 21 st century P51–P59 Current strategies in pulmonary rehabilitation P60–P69 Clinical issues in paediatric lung disease	Whittle & Fleming Rooms/3 rd
8.15am – 8.45am	BTS Journal Club	Paediatrics	Fleet Room/2 nd
8.30am – 10.00am	Spoken session	S1–S5 Predicting outcomes in interstitial lung disease	Elizabeth Windsor Room/5 th
8.30am – 10.15am	Symposium	Exacerbations of COPD	Churchill Auditorium/Ground
8.30am – 10.15am	Spoken session	S6–S11 Cellular interactions in the pathogenesis of pulmonary hypertension	Rutherford Room/4 th
8.30am – 10.15am	Spoken session	S12–S17 Tuberculosis screening: variations on a theme	Mountbatten Room/6 th
8.30am – 10.30am	Joint BTS/BALR symposium (part I)	The Darwinian legacy: evolution, pulmonary biology and the genetics of lung disease	Westminster Suite/4 th
8.45am – 10.15am	Spoken session	S18–S22 Sleep disorders in practice	St James's Suite/4 th
10.00am – 11.00am	COFFEE/TEA	Whittle & Fleming Rooms, Benjamin Britten Lounge/3 rd	
10.30am – 12.00pm	Spoken session	S23–S27 Causes and outcome in cough	St James's Suite/4 th
10.30am – 12.15pm	Symposium	Pulmonary rehabilitation	Churchill Auditorium/Ground
10.30am – 12.15pm	Symposium	Idiopathic pulmonary fibrosis	Mountbatten Room/6 th
10.45am – 12.30pm	Spoken session	S28–S33 Clinical problems in childhood	Abbey Room/4 th
10.45am – 12.30pm	Spoken session	S34–S39 Lung cancer and mesothelioma: clinical trials and clinical practice	Elizabeth Windsor Room/5 th
11.00am – 1.00pm	Joint BTS/BALR symposium (part II)	The Darwinian legacy: evolution, pulmonary biology and the genetics of lung disease	Westminster Suite/4 th
12.15pm – 2.00pm	LUNCH	Cash catering only	Pickwick Suite/1 st Whittle & Fleming Rooms/3 rd
12.30pm – 1.15pm	The Snell Memorial Lecture	New anti-TB drugs and how to test them	Churchill Auditorium/Ground
12.30pm – 2.00pm	Poster discussion	PI–P12 NIV in clinical practice: views from the front line	Elizabeth Windsor Room/5 th
1.00pm – 2.50pm	Poster discussion	P13–P27 Lung cancer: what's new in diagnostics and therapies	St James's Suite/4 th
1.20pm – 2.20pm	Update	The National Clinical Strategy for COPD and Asthma	Westminster Suite/4 th
1.30pm – 2.30pm	Poster discussion	P28–P34 Clinical observations in pulmonary vascular disease	Abbey Room/4 th
1.30pm – 3.15pm	Joint BTS/BPRS symposium	Asthma, genetics and the environment	Mountbatten Room/6 th
2.00pm – 3.45pm	Symposium	Tuberculosis	Churchill Auditorium/Ground
2.15pm – 4.00pm	Spoken session	S40–S45 Clinical studies into the pathogenesis of acute lung injury	Elizabeth Windsor Room/5 th
2.15pm – 4.15pm	Poster discussion	P35–P50 Delivering services in the 21 st century	Henry Moore Room/4 th
3.00pm – 4.00pm	Report	BTS Chairman's report and launch of the BTS Education Hub	Westminster Suite/4 th
3.00pm – 4.15pm	Poster discussion	P51–P59 Current strategies in pulmonary rehabilitation	St James's Suite/4 th
3.00pm – 4.30pm	COFFEE/TEA	Whittle & Fleming Rooms, Benjamin Britten Lounge/3 rd and Mountbatten Lounge/5 th (3.15pm–3.30pm)	
3.30pm – 4.45pm	Poster discussion	P60–P69 Clinical issues in paediatric lung disease	Mountbatten Room/6 th
4.15pm – 4.45pm	The President's Address	Transcending tribulations in training, transplantation and the Toon	Churchill Auditorium/Ground
4.45pm – 5.00pm	Presentation	Presentation of the BTS Medal	Churchill Auditorium/Ground
5.00pm – 5.30pm	BTS AGM	BTS Annual General Meeting (BTS members only)	Churchill Auditorium/Ground

Coffee and tea is complimentary ONLY during the coffee/tea break times shown above. Outside these times, drinks may be purchased from the cafe in the Pickwick Suite (1st floor), or the snack bar in the Whittle & Fleming Rooms (3rd floor).

THURSDAY 3 DECEMBER 2009

PROGRAMME at a glance

Time	Details		Location/Floor
8.00am – 9.00am	COFFEE/TEA	Whittle & Fleming Rooms/3 rd	
8.45am – 4.00pm	Poster viewing	P70–P81 Tuberculosis: epidemiology	Whittle & Fleming Rooms/3 rd
		P82–P93 Understanding CF lung disease and its consequences	
		P94–P107 COPD: exacerbations	
		P108–P123 Screening and treatment of tuberculosis	
		P124–P133 Clinical aspects of asthma	
		P134–P143 COPD: α 1-antitrypsin deficiency and other manifestations	
8.15am – 8.45am	BTS Journal Club	Occupational lung disease	Fleet Room/2 nd
8.30am – 10.00am	Spoken session	S46–S50 Airway challenges	Westminster Suite/4 th
8.30am – 10.00am	Spoken session	S51–S55 NIV: clinical aspects	Elizabeth Windsor Room/5 th
8.30am – 10.15am	Joint BTS/BTOG symposium	Mesothelioma	Churchill Auditorium/Ground
8.30am – 10.15am	Joint BTS/BPRS symposium	“Lost in translation”	St James’s Suite/4 th
8.30am – 10.15am	Spoken session	S56–S61 Epidemiology of chronic respiratory disease	Henry Moore Room/4 th
8.45am – 10.15am	Spoken session	S62–S66 Innate immune responses to bacteria	Abbey Room/4 th
8.45am – 10.30am	Symposium	Clinical controversies in cystic fibrosis	Mountbatten Room/6 th
9.00am – 10.30am	Spoken session	S67–S71 Disease pathogens in interstitial lung disease	Rutherford Room/4 th
10.00am – 11.00am	COFFEE/TEA	Whittle & Fleming Rooms, Benjamin Britten Lounge/3 rd	
10.30am – 12.15pm	Symposium	Plenary scientific	Churchill Auditorium/Ground
10.45am – 12.15pm	Spoken session	S72–S76 Systemic aspects of COPD	Mountbatten Room/6 th
11.00am – 12.15pm	BLF symposium	Successes of BLF research	Abbey Room/4 th
12.15pm – 2.00pm	LUNCH	Cash catering only	Pickwick Suite/1 st Whittle & Fleming Rooms/3 rd
12.30pm – 1.15pm	The BTS Lecture	Steroid resistance in COPD and severe asthma and how it may be reversed	Churchill Auditorium/Ground
1.45pm – 3.15pm	Symposium	T1–T6 BTS/BLF/BALR Young Investigators’ symposium	Elizabeth Windsor Room/5 th
1.45pm – 3.15pm	Poster discussion	P70–P81 Tuberculosis: epidemiology	St James’s Suite/4 th
1.45pm – 3.15pm	Poster discussion	P82–P93 Understanding CF lung disease and its consequences	Henry Moore Room/4 th
2.00pm – 3.30pm	Spoken session	S77–S81 Asthma: basic mechanisms	Rutherford Room/4 th
2.00pm – 3.45pm	Symposium	Acute lung injury	Churchill Auditorium/Ground
2.00pm – 3.45pm	Spoken session	S82–S87 New observations from physiology	Westminster Suite/4 th
2.00pm – 3.45pm	Poster discussion	P94–P107 COPD: exacerbations	Mountbatten Room/6 th
3.15pm – 4.15pm	COFFEE/TEA	Whittle & Fleming Rooms, Benjamin Britten Lounge/3 rd	
3.30pm – 5.15pm	Spoken session	S88–S93 In-vivo and in-vitro modelling in acute lung injury	Henry Moore Room/4 th
3.30pm – 5.30pm	Poster discussion	P108–P123 Screening and treatment of tuberculosis	St James’s Suite/4 th
4.00pm – 5.15pm	Poster discussion	P124–P133 Clinical aspects of asthma	Westminster Suite/4 th
4.00pm – 5.15pm	Poster discussion	P134–P143 COPD: α 1-antitrypsin deficiency and other manifestations	Abbey Room/4 th
4.00pm – 5.30pm	Spoken session	S94–S98 Cystic fibrosis from top to bottom	Elizabeth Windsor Room/5 th
4.00pm – 5.45pm	Symposium	Exploring the next generation of lung imaging modalities	Churchill Auditorium/Ground
4.00pm – 6.00pm	Symposium	‘Late breaking news’ – The management of empyema in 2010	Mountbatten Room/6 th
6.00pm – 7.30pm	The President’s Reception and Award Presentations – All welcome!		Benjamin Britten Lounge/3 rd

Coffee and tea is complimentary ONLY during the coffee/tea break times shown above. Outside these times, drinks may be purchased from the cafe in the Pickwick Suite (1st floor), or the snack bar in the Whittle & Fleming Rooms (3rd floor).

PROGRAMME at a glance**FRIDAY 4 DECEMBER 2009**

Time	Details	Location/Floor
8.00am – 9.00am	COFFEE/TEA	Whittle & Fleming Rooms/3 rd
8.45am – 2.00pm	Poster viewing	PI44–PI57 Managing a sleep disorder service PI58–PI73 Lung cancer: practice and epidemiology PI74–PI84 Causes and consequences of chronic cough PI85–PI94 COPD: identification and testing PI95–P210 Education and training P211–P218 Evaluating interventions in COPD P219–P227 Clinical implications of lung infection
8.15am – 8.45am	BTS Journal Club	Lung cancer Fleet Room/2 nd
8.30am – 10.15am	Symposium	Microbes and host-defence in lung disease Churchill Auditorium/Ground
8.30am – 10.15am	Spoken session	S99–S104 New techniques in diagnosis and treatment of respiratory diseases Westminster Suite/4 th
8.30am – 10.15am	Spoken session	SI05–SI10 COPD: cells and genes Mountbatten Room/6 th
8.45am – 10.30am	Spoken session	SI11–SI16 Pathways of vascular remodelling in PAH Abbey Room/4 th
10.00am – 11.00am	COFFEE/TEA	Whittle & Fleming Rooms, Benjamin Britten Lounge/3 rd
10.30am – 12.15pm	Joint BTS/BSACI symposium	New horizons in asthma Churchill Auditorium/Ground
10.30am – 12.15pm	UKRRC symposium	Infrastructure and career pathways Mountbatten Room/6 th
10.30am – 12.15pm	Spoken session	SI17–SI22 Molecular frontiers in lung cancer diagnosis and treatment Westminster Suite/4 th
10.30am – 12.15pm	Spoken session	SI23–SI28 Getting ahead in lung infection St James's Suite/4 th
10.45am – 12.30pm	Spoken session	SI29–SI34 COPD: counting the costs Elizabeth Windsor Room/5 th
10.45am – 12.15pm	Spoken session	SI35–SI39 Thoracic surgery and transplantation Abbey Room/4 th
12.15pm – 2.00pm	LUNCH	Cash catering only Pickwick Suite/1 st Whittle & Fleming Rooms/3 rd
12.30pm – 1.15pm	The Moran Campbell Lecture	Hypo-inflation Churchill Auditorium/Ground
1.15pm – 2.45pm	Spoken session	SI40–SI44 Managing the airway defect in cystic fibrosis Mountbatten Room/6 th
1.30pm – 2.30pm	Poster discussion	PI44–PI57 Managing a sleep disorder service Westminster Suite/4 th
1.30pm – 3.00pm	Poster discussion	PI58–PI73 Lung cancer: practice and epidemiology St James's Suite/4 th
1.30pm – 3.00pm	Poster discussion	PI74–PI84 Causes and consequences of chronic cough Henry Moore Room/4 th
1.30pm – 2.45pm	Poster discussion	PI85–PI94 COPD: identification and testing Abbey Room/4 th
1.45pm – 3.45pm	Symposium	The cardiopulmonary response to hypoxia Churchill Auditorium/Ground
2.00pm – 4.00pm	Poster discussion	PI95–P210 Education and training Rutherford Room/4 th
2.00pm – 3.15pm	Poster discussion	P219–P227 Clinical implications of lung infection Elizabeth Windsor Room/5 th
3.00pm – 4.00pm	Poster discussion	P211–P218 Evaluating interventions in COPD Abbey Room/4 th
3.00pm – 4.30pm	Spoken session	SI45–SI49 Is it asthma or not? Mountbatten Room/6 th
3.00pm – 4.45pm	COFFEE/TEA	Benjamin Britten Lounge/3 rd

Coffee and tea is complimentary **ONLY** during the coffee/tea break times shown above. Outside these times, drinks may be purchased from the cafe in the Pickwick Suite (1st floor), or the snack bar in the Whittle & Fleming Rooms (3rd floor).

ADDITIONAL SESSIONS

Other events during the Winter Meeting will include the following sessions. Further details may be found in the leaflets in the conference bags or by reading the screens in the conference centre.

WEDNESDAY 2 DECEMBER 2009

1.20pm – 2.20pm

Westminster Suite, 4th floor

SYMPOSIUM

The National Clinical Strategy for COPD and Asthma

Presentations from the Department of Health (England)

3.00pm – 4.00pm

Westminster Suite, 4th floor

SYMPOSIUM

The BTS Chairman's Report and launch of the BTS Education Hub

THURSDAY 3 DECEMBER 2009

11.00am – 12.15pm

Abbey Room, 4th floor

BRITISH LUNG FOUNDATION SYMPOSIUM

Successes of BLF research

Chaired by: Professor Stephen Spiro (London)

Enhancing patient self management of lung disease

Professor Martyn Partridge (London)

Diminished lung function at one year of age in infants born prematurely

Professor Janet Stocks (London)

BLF Chair: respiratory epidemiology

Professor Richard Hubbard (Nottingham)

Towards novel therapies for tuberculosis: identification of

IFN-gamma regulatory genes in BCG vaccinated infants

Professor Melanie Newport (Brighton)

12.30pm – 1.30pm

Henry Moore Room, 4th floor

BTS All-Party Parliamentary Group on Global TB, TB Alert PCT survey launch: national minimum standards for TB treatment

FRIDAY 4 DECEMBER 2009

8.45am – 10.15am

Elizabeth Windsor Room, 5th floor

SYMPOSIUM

INTEGRATED RESPIRATORY CARE – WHAT EVERYONE IN SECONDARY CARE NEEDS TO KNOW. PREPARING FOR THE COPD NATIONAL STRATEGY

Chaired by: Professor Tony Davison (Southend) and Professor Michael Morgan (Leicester)

What's the latest?

Dr Robert Winter (Cambridge)

“Out of the frying pan...”

Dr John Williams (Halton)

Seize the day

Glenda Esmond (Barnet)

Summary: what BTS can do and what you can do for yourselves

Professor Michael Morgan (Leicester)

BRITISH THORACIC SOCIETY OPEN MEETINGS

The programme will also include open meetings of some of the BTS Specialist Advisory Groups (SAGs) and Guideline Groups. Further details may be found in the leaflets in the conference bags or by reading the screens in the conference centre.

WEDNESDAY 2 DECEMBER 2009

Time	Details	Location/Floor
10.45am – 11.45am	BTS TB SAG	Henry Moore Room/4 th
12.30pm – 1.30pm	BTS COPD SAG (discussion of NICE guideline)	Henry Moore Room/4 th
1.00pm – 2.00pm	BTS Oxygen champions	Rutherford Room/4 th
2.30pm – 3.30pm	BTS Interventional procedures SAG	Rutherford Room/4 th

THURSDAY 3 DECEMBER 2009

Time	Details	Location/Floor
10.30am – 12.00pm	BTS Nurse advisory group	St James's Suite/4 th
11.00am – 12.00pm	BTS Lung cancer and mesothelioma SAG	Rutherford Room/4 th
11.00am – 12.00pm	BTS Specialist trainee advisory group	Henry Moore Room/4 th
12.30pm – 1.30pm	BTS Occupational and environmental lung health SAG	Abbey Room/4 th
12.30pm – 1.30pm	BTS Cystic fibrosis SAG	Westminster Suite/4 th
12.30pm – 1.30pm	BTS Fitness for surgery guidelines 2010	Elizabeth Windsor Room/5 th
1.00pm – 2.00pm	BTS Sleep apnoea SAG	Rutherford Room/4 th

FRIDAY 4 DECEMBER 2009

Time	Details	Location/Floor
8.45am – 10.15am	Integrated respiratory care	Elizabeth Windsor Room/5 th
9.00am – 10.00am	BTS draft air travel guideline	Rutherford Room/4 th
12.30pm – 1.30pm	BTS Critical care SAG	Rutherford Room/4 th
12.45pm – 1.45pm	BTS pulmonary infection SAG	Elizabeth Windsor Room/5 th

The British Thoracic Society President's Reception and Award Presentations


Thursday 3 December, 6.00pm to 7.30pm
Benjamin Britten Lounge, 3rd floor, QEII Conference Centre



All participants are warmly invited to join us on this special occasion. The presentations will be made for the annual BTS/BLF/BALR Young Investigator of the Year Awards, as well as the Medical Student Award for the medical student who was judged to have submitted the best abstract. In addition the IMPRESS Award for Innovation in Provision of Respiratory Care will be presented, jointly sponsored by BTS and the General Practice Airways Group (GPIAG).

FLOOR PLAN OF THE EXHIBITION STANDS

Exhibitors and stand numbers



Whittle & Fleming Rooms, 3rd floor

10	Actelion
	Pharmaceuticals UK Ltd
2	Aerocrine
39	Air Products
11, 12 & 13	AstraZeneca
7	BOC Healthcare
6&9	Boehringer Ingelheim/ Pfizer
28	CareFusion
33	Cellestis
29, 30, 37 & 38	Chiesi Ltd
40	DeVilbiss Healthcare
32	Fisher & Paykel Healthcare
36	Forest Laboratories UK Ltd
31	Genzyme
16, 17, 24 & 25	GlaxoSmithKline/Allen & Hanburys
27	Hitachi Medical Systems
21	Merck Sharp & Dohme Ltd
43	Nutricia UK
18, 19, 20, 22 & 23	Nycomed
14	Olympus KeyMed
8	Oxford Immunotec
41	Pentax Life Care
26	Pharmaxis
4 & 5	Philips Respiroics
45	PROACT Medical
15	ProStrakan Group plc
44	ResMed (UK) Ltd
3	Rocket Medical
34 & 35	Teva UK Ltd
42	UK Medical
1	Vitalograph

Benjamin Britten Lounge, 3rd floor

63	Blackwell
----	-----------

Charity and non-commercial stands

Benjamin Britten Lounge, 3rd floor

C57	Association of Chartered Physiotherapists in Respiratory Care (ACPRC)
C51	Association of Respiratory Nurse Specialists (ARNS)
C59	Association for Respiratory Technology and Physiology (ARTP)
C62	British Lung Foundation
C49	British Thoracic Society
C60	Education for Health
C46	GPIAG and PCRJ
C50	IMPRESS
C48	The Met Office
C61	The National Council for Palliative Care (NCPC)
C55	NHS Improvement Partnership
C47	The NHS Centre for Health and Social Care
C53	Primary Ciliary Dyskinesia (PCD) Family Support Group UK
C56	Pulmonary Hypertension Association (PHA) UK
C52	Respiratory Education UK
C54	Sleep Apnoea Trust
C64	TB Alert
C58	Thorax (BMJ) Group)

Wednesday 2 December 2009

8.00am – 9.00am

COFFEE/TEA will be served in the Whittle & Fleming Rooms, 3rd floor

8.45am – 4.00pm

Whittle & Fleming Rooms, 3rd floor

POSTER VIEWING

Authors present: 10.00am – 11.00am

PI–PI2

NIV in clinical practice: views from the front line

Discussion of abstracts will take place from 12.30pm to 2.00pm in the Elizabeth Windsor Room, 5th floor

PI3–P27

Lung cancer: what's new in diagnostics and therapies

Discussion of abstracts will take place from 1.00pm – 2.50pm in the St James's Suite, 4th floor

P28–P34

Clinical observations in pulmonary vascular disease

Discussion of abstracts will take place from 1.30pm to 2.30pm in the Abbey Room, 4th floor

P35–P50

Delivering services in the 21st century

Discussion of abstracts will take place from 2.15pm to 4.15pm in the Henry Moore Room, 4th floor

P51–P59

Current strategies in pulmonary rehabilitation

Discussion of abstracts will take place from 3.00pm to 4.15pm in the St James's Suite, 4th floor

P60–P69

Clinical issues in paediatric lung disease

Discussion of abstracts will take place from 3.30pm to 4.45pm in the Mountbatten Room, 6th floor

8.15am – 8.45am

Fleet Room, 2nd floor

THE BTS JOURNAL CLUB

Paediatrics

Dr David Spencer (Newcastle upon Tyne)

8.30am – 10.00am

Elizabeth Windsor Room, 5th floor

SPOKEN SESSION: S1 – S5

Predicting outcomes in interstitial lung disease

Chaired by: Professor R du Bois (Denver) and Professor R Hubbard (Nottingham)

8.35am **S1**

Elevated nocturnal oxygen desaturation index predicts higher short term mortality in interstitial lung disease
TJ Corte, S Talbot, SJ Wort, AU Wells

8.50am **S2**

Gene-set analysis of lung samples from progressive, fibrotic pulmonary sarcoidosis shows pattern similar to hypersensitivity pneumonitis
S Sanderson, HE Lockstone, N Kulakova, D Baban, CI Newbold, AJ McMichael, L-P Ho

9.05am **S3**

Interstitial lung disease in the inflammatory myositides: exacerbations of muscle disease are not paralleled by worsening of pulmonary function
F Chua, AM Higton, K McNulty, S Grubnic, EJ Edwards, PDW Kiely

SCIENTIFIC PROGRAMME

9.20am **S4**

Identifying anxiety and depression in interstitial lung disease: use of a simple outpatient screening tool
MD Shipley, T Hardy, K Heslop, IA Forrest

9.35am **S5**

Physiological deterioration versus stabilisation in myositis-associated interstitial lung disease: phenotypic differences and influence of immunosuppressive treatment
AM Higton, PDW Kiely, K McNulty, S Grubnic, EJ Edwards, F Chua

8.30am – 10.15am

Churchill Auditorium, Ground floor

SYMPOSIUM

EXACERBATIONS OF COPD

Chaired by: Dr Nick Hopkinson (London) and Professor Wisia Wedzicha (London)

8.30am

Human models of exacerbations

Dr Patrick Mallia (London)

8.55am

Temporal clustering of exacerbation; data and implications for trial design

Dr John Hurst (London)

9.20am

Inactivity and exacerbation – is there a connection

Dr Judith Garcia-Aymerich (Barcelona)

9.45am

Antioxidant therapy to reduce exacerbation of COPD

Professor Nan-shan Zhong (Guangzhou)

8.30am – 10.15am

Rutherford Room, 4th floor

SPOKEN SESSION: S6 – S11

Cellular interactions in the pathogenesis of pulmonary hypertension

Chaired by: Dr Luke Howard (London) and Dr David Welsh (Glasgow)

8.35am **S6**

Regulation of endothelin-1 production by the transforming growth factor/bone morphogenetic protein pathway in human pulmonary artery smooth muscle cells

PM de Souza, NW Morrell, PD Upton, JES Park, SJ Wort

8.50am **S7**

Tumour necrosis factor α , bone morphogenetic protein 9 and cyclosporine affect expression of bone morphogenetic protein type 2 receptor in human pulmonary artery endothelial cells – potential roles in the pathogenesis of pulmonary arterial hypertension
M Nikolic, L Long, A Crosby, NW Morrell

9.05am **S8**

TRAIL expression is increased in the rat monocrotaline model of pulmonary arterial hypertension
AG Hameed, T Vinogradova, SE Francis, CMH Newman, DC Crossman, A Lawrie

9.20am **S9**

Osteopontin expression is increased prior to haemodynamic alterations in the rat monocrotaline model of pulmonary arterial hypertension
T Vinogradova, AG Hameed, SE Francis, CMH Newman, DC Crossman, A Lawrie

SCIENTIFIC PROGRAMME

- 9.35am S10**
Regulation of expression and function of osteoprotegerin in pulmonary artery smooth muscle cells in vitro
C Paiva, SE Francis, CMH Newman, DC Crossman, A Lawrie
- 9.50am S11**
Fat fed ApoE/IL-1RI double deficient mice are protected from atherosclerosis but develop severe pulmonary hypertension.
AG Hameed, SE Francis, M Neilan, S Parmar, DC Crossman, A Lawrie

8.30am – 10.15am**Mountbatten Room, 6th floor****SPOKEN SESSION: S12 – S17****Tuberculosis screening: variations on a theme**

Chaired by: Professor Ajit Lalvani (London) and Professor Peter Ormerod (Blackburn)

- 8.35am S12**
Systems biology approaches characterize the host response to tuberculosis
MPR Berry, CM Graham, SJ Bloch, T Oni, KA Wilkinson, RJ Wilkinson, OM Kon, J Banchereau, D Chaussabel, A O'Garra
- 8.50am S13**
Contact screening with single step TIGRA testing and risk of active Tb infection: the Leicester cohort analysis
P Haldar, H Thuraisingham, W Hoskyns, G Woltmann
- 9.05am S14**
New entrant screening for latent tuberculosis using IGRA testing alone
LP Ormerod
- 9.20am S15**
Outcomes and cost of MDR TB in Leeds 1996 – 2009
RY Ahmed, TGD Capstick, JP Watson
- 9.35am S16**
Five years of support for a tuberculosis programme in rural Zimbabwe: what has been achieved?
KM Scott, FJC Millard, RM Smith, E Manomano, M Glenshaw, RD Barker
- 9.50am S17**
Tuberculosis and HIV in health care workers
JP Crofts, M Kruijshaar, V Delphech, F Ncube, D Quinn, I Abubakar

8.30am – 10.30am**Westminster Suite, 4th floor****SYMPOSIUM****JOINT BTS/BALR SYMPOSIUM PART I: THE DARWINIAN LEGACY – EVOLUTION, PULMONARY BIOLOGY AND THE GENETICS OF LUNG DISEASE****Evolution of the pulmonary system and the molecular basis of lung development**

Chaired by: Dr Colin Bingle (Sheffield) and Professor Terry Tetley (London)

- 8.30am** 200 years of evolution
Professor Tim Birkhead (Sheffield)
- 9.00am** Ventilation in birds and other dinosaurs
Dr Jonathan Codd (Manchester)

Wednesday 2 December 2009

- 9.30am** Design on a need to have basis: is there a logical basis of the evolutionary multiplicity of the gas exchangers?
Professor John Maina (Witwatersrand)
- 10.00am** The branching programme of lung development
Dr Ross Metzger (San Francisco)

8.45am – 10.15am**St James's Suite, 4th floor****SPOKEN SESSION: S18 – S22****Sleep disorders in practice**

Chaired by: Dr Sophie West (Newcastle upon Tyne) and Dr Adrian Williams (London)

- 8.50am S18**
Prevalence of obstructive sleep apnoea (OSA) in 58 patients with diabetic macular oedema (DME)
RH Mason, SD West, V Chong, JR Stradling
- 9.05am S19**
Impact of thyroid function testing in patients with obstructive sleep apnoea syndrome: a single centre experience over a decade
B Jayaraman, P Farrow
- 9.20am S20**
Has the change to limited polysomnography scoring using modified AASM criteria altered clinical practice?
Dr Aung, Dr Bianchi
- 9.35am S21**
Prevalence of obstructive sleep apnoea (OSA) in 76 patients with abdominal aortic aneurysms (AAA), and it's relation to rate of expansion
RH Mason, M Hardinge, JMT Perkins, M Kohler, JR Stradling
- 9.50am S22**
Effective interventions to reduce noise on a general medical ward
AC Hutchings, JCT Pepperell, H Potter

10.00am – 11.00am

COFFEE/TEA will be served in the Whittle & Fleming Rooms and Benjamin Britten Lounge, 3rd floor

10.30am – 12.00pm**St James's Suite, 4th floor****SPOKEN SESSION: S23 – S27****Causes and outcome in cough**

Chaired by: Professor Ian Pavord (Leicester) and Professor Ashley Woodcock (Manchester)

- 10.35am S23**
Influences of smoking and COPD on objective cough frequency
H Sumner, A Kelsall, AL Lazaar, U Kolsum, D Singh, AA Woodcock, JA Smith
- 10.50am S24**
Cough, airway inflammation and asthma control
PA Marsden, B Ibrahim, L Yates, A Woodcock, SJ Fowler, J Smith
- 11.05am S25**
The long term outcome of patients with unexplained chronic cough
N Yousaf, SS Birring, ID Pavord

Wednesday 2 December 2009

11.20am S26

Funduplication for chronic cough: six years experience
S Faruqi, P Sedman, AH Morice

11.35am S27

Long-term low dose erythromycin for unexplained chronic cough: a double blind, randomised, placebo controlled trial
N Yousaf, S Matos, SS Birring, ID Pavord

10.30am – 12.15pm

Churchill Auditorium, Ground floor

SYMPOSIUM

PULMONARY REHABILITATION

Chaired by: *Dr Charlotte Bolton (Nottingham) and Dr William Man (London)*

10.30am Introduction and clinical overview
Professor Michael Polkey (London)

10.55am Current understanding of the molecular biology of muscle wasting
Dr Gerald Supinski (Kentucky)

11.20am How can I improve exercise performance in vivo?
Dr Michael Steiner (Leicester)

11.45am Early PR after AECOPD re-evaluated
Professor John Moxham (London)

10.30am – 12.15pm

Mountbatten Room, 6th floor

SYMPOSIUM

IDIOPATHIC PULMONARY FIBROSIS

Chaired by: *Dr Nik Hirani (Edinburgh) and Dr Toby Maher (London)*

10.30am Concepts in the pathogenesis of IPF
Dr Gisli Jenkins (Nottingham)

10.55am Prognostic scoring systems
Professor Athol Wells (London)

11.20am What is an acute exacerbation of IPF?
Dr Harold R Collard (San Francisco)

11.45am Future treatments for IPF
Professor Ron du Bois (Denver)

10.45am – 12.30pm

Abbey Room, 4th floor

SPOKEN SESSION: S28 – S33

Clinical problems in childhood

Chaired by: *Professor Anne Greenough (London) and Dr Colin Wallis (London)*

10.50am S28

Childhood Asthma in North East Scotland – a 45-year perspective
G Malik, N Tagiyeva, G McNeill, S Turner

11.05am S29

Size at birth, asthma symptoms and respiratory function in a cohort of prepubertal children
A Maitra, A Sherriff, AJ Henderson

11.20am S30

Towards a metabolomic approach to respiratory disease in childhood: feasibility and acceptability of a novel breath-sampling procedure and initial breath analysis data
F Gahleitner, C Guallar-Hoyas, G Blackburn, CS Beardsmore, CLP Thomas, H Pandya

SCIENTIFIC PROGRAMME

11.35am S31

Safety and tolerability of omalizumab in children with inadequately controlled moderate-to-severe allergic (IgE-mediated) asthma
H Milgrom, J Fink, A Fowler-Taylor, C Fernandez Vidaurre, M Blogg

11.50am S32

Paediatric empyema management in the UK
M Thomas, D Cliff, S Beaton, SP Rushton, J Paton, DA Spencer

12.05pm S33

Mild to moderate pulmonary hypertension in children with sickle cell disease is due to increased pulmonary blood flow secondary to anaemia rather than elevated pulmonary vascular resistance
R A Chaudry, M Cikes, T Karu, C Hutchinson, S Ball, G Sutherland, M Rosenthal, A Bush, S Crowley

10.45am – 12.30pm

Elizabeth Windsor Room, 5th floor

SPOKEN SESSION: S34 – S39

Lung cancer and mesothelioma: clinical trials and clinical practice

Chaired by: *Dr David Baldwin (Nottingham) and Dr Michael Peake (Leicester)*

10.50am S34

An early exercise intervention prevents quadriceps weakness after thoracotomy for non small cell lung cancer (NSCLC): randomised controlled trial
G Arbane, D Jackson, D Tropman, R Garrod

11.05am S35

Early detection of lung cancer; a social marketing evaluation
TK Rogers, V Athey, A Tod, SJ Walters, R Suckling

11.20am S36

Role of CT head in lung cancer staging in patients with no neurological symptoms
S Manapragada, R Khashkhasha, M Thirumaran, P Blaxill, S Meghjee

11.35am S37

Mesothelioma as a metastatic disease: a post-mortem study
FJH Brims, A Gandhi, N Olsen, AW Musk, YCG Lee

11.50am S38

The incidence and distribution of metastases from pleural malignant mesothelioma at post mortem in the Bristol area (2005–2008)
RS Finn, N Ibrahim, C Hooper, NA Maskell

12.05pm S39

Systemic biochemical markers are important in mortality prediction in mesothelioma: a novel prediction model
FJH Brims, A Asimwe, AJ Chauhan

SCIENTIFIC PROGRAMME

11.00am – 1.00pm

Westminster Suite, 4th floor

SYMPOSIUM

JOINT BTS/BALR SYMPOSIUM PART II: THE DARWINIAN LEGACY – EVOLUTION, PULMONARY BIOLOGY AND THE GENETICS OF LUNG DISEASE

Genetics of lung disease, host/pathogen evolution and the development of respiratory medicine

Chaired by: Dr Kim Harrison (Swansea) and Professor Ann Millar
(Bristol)

11.00am Evolution and respiratory genetics
Professor Peter Le Souef (Perth)

11.30am Dealing with host-pathogen experience in real time: the
SARS experience
Professor Nan-shan Zhong (Guangzhou)

12.00pm Outwitting the host's response: mechanisms of bacterial
pathogenesis
Professor Tim Mitchell (Glasgow)

12.30pm Flu virus evolution and the history of flu pandemics
Professor John Oxford (London)

12.15pm – 2.00pm

LUNCH will be available to purchase in the Cafe in the Pickwick
Suite, 1st floor, and the Snack Bar in the Whittle & Fleming Rooms,
3rd floor

12.30pm – 1.15pm

Churchill Auditorium, Ground floor

SNELL MEMORIAL LECTURE

New anti-TB drugs and how to test them

Professor Denis Mitchison (London)

Introduced by: Professor Paul Corris (Newcastle upon Tyne)

12.30pm – 2.00pm

Elizabeth Windsor Room, 5th floor

POSTER DISCUSSION: P1 – P12

NIV in clinical practice: view from the frontline

Chaired by: Dr Robert Angus (Liverpool) and Dr Craig Davidson (London)

P1 Non-invasive ventilation in motor neurone disease: the
utility of the Epworth sleepiness scale as an outcome
measure

LH Piggin, EW Thornton, RM Angus, B Chakrabarti,
CA Young

P2 Predictors of successful domiciliary non-invasive
ventilation for motor neurone disease in a district
general hospital

RJ Parker, GV Robinson, AD McGown, CWH Davies

P3 Outcomes of patients with acute exacerbations of
COPD and decompensated

A Ponnuswamy, A Abdul, RM Angus

P4 NIV in COPD patients with acute hypercapnic
respiratory failure; outcome in patients with radiological
evidence of consolidation

SR Henderson, TJ Tull, CR Sander, JL Brown

P5 Impact of domiciliary non invasive ventilation
(NIV) service in chronic ventilatory disorder on
hospitalisation and quality of life – a Grimsby
experience

A Dwarakanath, H O' Flynn

Wednesday 2 December 2009

P6 Changes in pulmonary function tests following initiation
of non-invasive ventilation in patients with type 2
respiratory failure secondary to obesity

S Gledhill, TW Felton, S Johnson, N Clayton, AM Bentley

P7 Non-invasive ventilation training. A simulated approach
for health care professionals

SG McQueen, M Dickinson, M Pimblett

P8 An audit of decision making when commencing and
during bi-level positive airway pressure ventilation in a
district general setting

R Francis, M Harley, A Wickham, JA Hughes

P9 Domiciliary ventilator initiation – suitable for day case?

E Sayell, BV Prathibha

P10 The severity of acidosis at presentation is not linked
to survival to hospital discharge in patients with acute
Type 2 respiratory failure

H Rupani, H Artis, R Agrawala, V Jones, S Fletcher,
KMA O'Reilly

P11 Patient satisfaction with an acute non invasive
ventilation (NIV) service

K Walsh, AP Nataraja, MDL Morgan

P12 A retrospective evaluation of home initiation for long
term non-invasive ventilatory support

JM Palmer, PD Hughes

1.00pm – 2.50pm

St James's Suite, 4th floor

POSTER DISCUSSION: P13 – P27

Lung cancer: what's new in diagnosis and therapies

Chaired by: Dr Richard Harrison (Stockton-on-Tees) and Dr Jeremy
George (London)

P13 Highly sensitive assay to detect hepcidin in biological
fluids – presence of hepcidin in pleural fluid
A Sangwaiya, JD Arnold, V Manglam, M Thursz,
F Geoghegan, M Busbridge

P14 Prevention of skin metastasis in malignant mesothelioma
with prophylactic irradiation of tracts (PIT): is the
difference in research evidence due to the discrepancy
between distance from pleural entry point and the skin
scar?

K L Hambleton, C Favier-Finn, DR Baldwin

P15 Assessing a panel of five biomarkers in sputum of
patients with and without lung cancer

R Ghosal, KE Lewis, PJ Kloer, C Davies, PD Lewis

P16 PET scanning increases the need for mediastinal staging
procedures in lung cancer

CM Free, ARL Medford, S Agrawal, JJ Entwisle, JA Bennett,
A Nakas

P17 The role of bronchoscopy in peripheral lung lesions

TS Jordan, H Tan, M Walshaw, E Spencer, A Collins,

M Ledson, A Ashish, K Mohan

P18 Prevalence of cerebral recurrence following resection
for non small cell lung cancer in the post PET era – is
there a need for pre-operative CT brain and is it cost
effective?

LM Jones, L Burke, SRA West, PK Plant

P19 Unexpected findings complicate the use of
FDG-PET CT scans in the investigation of lung
malignancy – experience of one cancer network

A Murray

Wednesday 2 December 2009

- P20** Pre-PET CT guided biopsy of solitary pulmonary nodules (SPNs) reduces the benign resection rate in a population with high incidence of granulomatous disease without an unacceptable complication rate
J Evans, YE Ong, S Grubnic, N Walters, F Chua, A Draper
- P21** Prospective data of continuous hyperfractionated accelerated radiotherapy (CHART) for non-small cell lung cancer (NSCLC) – clinical outcome and patient satisfaction survey of the Northern Regional Cancer Centre
HW Loo, R Klapper, P Mulvenna, R Mcmenemin, F McDonald, P Atherton, G Mazdai
- P22** Are invasive diagnostic tests performed justifiably in patients with suspected pleural/pulmonary malignancy?
AO Dunscombe, RK Sinha
- P23** Analysis of methods of obtaining tissue diagnosis in patients with suspected lung cancers
AK Allouni, D Lau, T Meagher, E Woo, A Prasad
- P24** Secular changes in the use of investigations and training opportunities in a lung cancer unit
SP Hanley
- P25** A performance and theoretical cost analysis of a recently developed endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) service in a UK respiratory centre
ARL Medford, S Agrawal, CM Free, JA Bennett
- P26** Comparison of deep versus light sedation on doctor, nurse, and patient assessments during fibreoptic bronchoscopy with endobronchial ultrasound guided FNAC procedures (EBUS-TBNA)
S Naik, A Mohan, M Munavvar, S Laurence
- P27** The impact of pre-medical thoracoscopy thoracic ultrasound on pleural access and prediction of septation
ARL Medford, S Agrawal, JA Bennett, CM Free, JJ Entwisle

1.30pm – 2.30pm

Abbey Room, 4th floor

POSTER DISCUSSION: P28 – P34

Clinical observations in pulmonary vascular disease

Chaired by: *Dr Joanna Pepke-Zaba (Cambridge) and Dr John Wort (London)*

- P28** A multi-dimensional composite score using non-invasive baseline variables to predict mortality in patients with pulmonary arterial hypertension
WN Lee, S Kerridge, AJ Peacock, MK Johnson
- P29** The relationship between mean and systolic pulmonary artery pressure in idiopathic (IPAH), connective tissue disease associated (CTDPH) and chronic thromboembolic pulmonary hypertension (CTEPH)
SF Crawley, MK Johnson, AJ Peacock
- P30** Predictors of early and late mortality in acute pulmonary embolism
A Singanayagam, JD Chalmers, C Scally, MZ Al-Khairalla, L Leitch, AT Hill
- P31** Comparison of outcome following heart/lung transplantation for chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension
R Venkateswaran, D Jenkins, J Dunning, S Tsui, J Wallwork, J Parmar

SCIENTIFIC PROGRAMME

- P32** Incidence of non-diagnostic CTPA images in the pregnant population; a four year experience
EC Potton, S Marsh, C Hasford
- P33** Changing outcomes in different types of pulmonary arterial hypertension
E Soon, CM Treacy, MR Toshner, R Mackenzie Ross, NJ Doughty, KK Sheares, NW Morrell, J Pepke-Zaba
- P34** The relationship between the mean and systolic pulmonary artery pressures in pulmonary arterial hypertension
RV MacKenzie Ross, M Toshner, E Soon, J Pepke-Zaba

1.30pm – 3.15pm

Mountbatten Room, 6th floor

SYMPOSIUM

JOINT BTS/BPRS SYMPOSIUM: ASTHMA, GENETICS AND THE ENVIRONMENT

Chaired by: *Professor Andrew Greening (Edinburgh) and Professor Peter Le Souef (Perth)*

Asthma genes and environmental interactions

- 1.30pm** Picking populations and finding genes
Professor Miriam Moffatt (London)
- 1.55pm** Phenotype and genotype inter-relationships in childhood
Professor Adnan Custovic (Manchester)

Early life environmental exposures: problems and solutions

- 2.20pm** The developed world
Professor Paul Cullinan (London)
- 2.45pm** The developing world
Professor Jonathan Grigg (London)

2.00pm – 3.45pm

Churchill Auditorium, Ground floor

SYMPOSIUM

TUBERCULOSIS

Chaired by: *Dr Marc Lipman (London) and Dr John Watson (Leeds)*

- 2.00pm** TB in the UK: are we different from the rest of Europe?
Dr Ibrahim Abubakar (Health Protection Agency)
- 2.30pm** Can we make an effective TB vaccine?
Dr Helen McShane (Oxford)
- 3.00pm** HIV and TB: an update
Dr Marc Lipman (London)

2.15pm – 4.00pm

Elizabeth Windsor Room, 5th floor

SPOKEN SESSION: S40 – S45

Clinical studies into the pathogenesis of acute lung injury

Chaired by: *Professor Andrew Fisher (Newcastle upon Tyne) and Professor Ann Millar (Bristol)*

- 2.20pm S40** Lipopolysaccharide inhalation drives pulmonary inflammation and causes alveolar epithelial and endothelial activation/injury in an in vivo human model of acute lung injury
M Shyamsundar, S McKeown, C Calfee, B Thompson, C O’Kane, D Thickett, T Craig, M Matthay, JS Elborn, D McAuley

SCIENTIFIC PROGRAMME

- 2.35pm S41**
Increasing pulmonary neutrophil gelatinase associated lipocalin (NGAL) is associated with resolution of pulmonary oedema and ICU survival in acute lung injury
CM O’Kane, TR Craig, MJ Duffy, M Shyamsundar, DF McAuley
- 2.50pm S42**
The effect of ex-vivo lung perfusion on pro-and anti-inflammatory cytokines in the human lung
DM Karamanou, S Bean, M Prabhu, HR Walden, S Clark, PA Corris, JH Dark, AJ Fisher
- 3.05pm S43**
Defective efferocytosis due to aberrant intra-pulmonary steroid metabolism contributes to persistent inflammation in ARDS
CR Bassford, F Gao, GD Perkins, D Thickett
- 3.20pm S44**
Oncostatin-M (OSM) is produced by inflammatory cells and drives CXCL8 from resident pulmonary cells in a model of acute lung injury (ALI)
STW McKeown, DF McAuley, CM O’Kane
- 3.35pm S45**
Polymorphisms in inflammatory pathway genes predispose patients to adverse outcomes after cardiopulmonary bypass surgery
RJ Hewitt, DD Melley, LR Hector, P Pantelidis, SJ Finney, TW Evans, GJ Quinlan, AL Lagan

2.15pm – 4.15pm**Henry Moore Room, 4th floor****POSTER DISCUSSION: P35 – P50****Delivering services in the 21st century***Chaired by: Dr Tony Davison (Southend), Dr Louise Restrict (London) and Ms Jane Scullion (Leicester)*

- P35** Tablet PC to evaluate respiratory patient preference and satisfaction using the 18-element Consultation Specific Questionnaire (CSQ)
M Alhajji, A Jeffrey, A Datta
- P36** Use of the British Lung Foundation Helpline
CA Paxton, MT Pilling, JE Earis, RM Angus
- P37** Disease severity and APACHE II scores of respiratory inpatients on a ward based respiratory care unit
S Thomas, G Jones, JA Corless
- P38** Post-ITU patients on a general respiratory ward in a district general hospital; outcome and resource implications
A Manuel, AJ Moore, RJ Parker, J Bowen, I Patel, A May, LC Castle, SD Waddy, REK Russell, J Wiggins
- P39** CXR reporting by respiratory consultants: an old service fit for the 21st century
AW Fayed, T Brown, P Andrews, D Laws
- P40** The implication of contrast induced nephropathy for lung cancer services
R Rabbani, R Parasa, M Haris, J Gallagher, G Bockeler, M Winson
- P41** Experiences of direct access CT scanning for general practitioners and implications for investigation of possible lung cancer
B Lowry, D Hughes, JA Corless

Wednesday 2 December 2009

- P42** Setting up of a Trust wide oxygen prescribing policy – a five year experience
PC Deegan, L Vincent, K Parker
- P43** Does the sheer prevalence of lung diseases such as asthma and COPD lead to the overlooking of restrictive pulmonary defects?
M Tahir, LA O’Byrne, E Starren, NJ Roberts, IS Patel, R Haffenden, MR Partridge
- P44** Barriers to healthcare professionals encouraging self management in asthma and COPD
I Younis, NJ Roberts, MR Partridge
- P45** Undercoding in a district general hospital: financial implications and funding opportunities
J Fingleton, J Pickering, S Illes
- P46** Impact of a community respiratory assessment service on evidence based prescribing in primary care
IS Patel, H Milestone, S Dawson, L Killeen, K Bertenshaw, R Haffenden, NR Roberts, MR Partridge
- P47** The importance of coding position when defining hospitalised COPD populations
PP Walker, G Tack, E Thompson, H Crone, G Flatt, MG Pearson
- P48** Palliative care service provision for chronic obstructive pulmonary disease (COPD) patients – mapping current and proposed service development against palliative care gold standards
KL Buxton, CM Roberts, RJ Buckingham, N Pursey, RA Stone
- P49** COPD case finding pilot evaluation ‘Finding Our Missing Thousands’
L Chandler, H Laird, L Wheeler, E Smith, SPL Meghjee
- P50** Smoking prevalence and attitudes in medical inpatients in Liverpool
S Huq, MI Hasan, A Nwosu, J Hadcroft, M Walshaw

3.00pm – 4.00pm**Westminster Suite, 4th floor****BTS CHAIRMAN’S PRESENTATION****The future direction for BTS and launch of the BTS Education Hub****3.00pm – 4.15pm****St James’s Suite, 4th floor****POSTER DISCUSSION: P51 – P59****Current strategies in pulmonary rehabilitation***Chaired by: Dr Rachel Garrod (London) and Professor Sally Singh (Leicester)*

- P51** Pilot randomised controlled trial of a seven week, disease specific self management programme for patients with COPD: BELLA (BEtter Living with Long term Airways disease study)
SJC Taylor, R Sohanpal, SA Bremner, A Devine, S Eldridge, CJ Griffiths
- P52** A randomised controlled trial of a Self-management Programme of Activity, Coping & Education: SPACE for COPD
LD Apps, K Wagg, L Sewell, J Williams, SJ Singh, SJ Singh
- P53** Pulmonary rehabilitation using the SPACE (A Self-management Programme of Activity, Coping and Education) manual at home: a randomised controlled trial
K Wagg, E Wilcock, J Williams, L Sewell, M Steiner, M Morgan, S Singh

Wednesday 2 December 2009

- P54** COPD patients' beliefs and expectations of pulmonary rehabilitation
J O'Connor, T Cartwright, C Lee, L Nabarro, P Evans, A Clow, D Peters, SL Elkin
- P55** Large scale community pulmonary rehabilitation: more than a question of numbers
O Reddington, A Telford, V Stott, G South
- P56** Patient preferences for quality of life measures in pulmonary rehabilitation (PR): Breathing Problems Questionnaire Short Version (BPQ-SV) vs Chronic Respiratory Questionnaire Self Report (CRQ-SR)
H Best, D Dyer, J Bott
- P57** Patients with severe COPD referred for pulmonary rehabilitation who never attend: use of hospital resources and risk of death
Z Abrahams, A Williamson, S Purcell, H Broomfield, M Stern
- P58** Nutritional assessment in pulmonary rehabilitation
D Proud, N Gale, T Lines, E Hilsden, CE Bolton
- P59** Evaluation of the Surrey Information on Function Tool (SIFT) as a functional outcome measure for Pulmonary Rehabilitation (PR)
J Callaghan, F Dyer, J Bott

3.00pm – 4.30pm

COFFEE/TEA will be served in the Whittle & Fleming Rooms and Benjamin Britten Lounge, 3rd floor and the Mountbatten Lounge, 5th floor (3.15pm – 3.30pm)

3.30pm – 4.45pm

Mountbatten Room, 6th floor

POSTER DISCUSSION: P60 – P69

Clinical issues in paediatric lung disease

Chaired by: Professor Andrew Bush (London) and Dr David Spencer (Newcastle upon Tyne)

- P60** A regional survey of paediatric consultants' practices and attitudes in the management of spinal muscular atrophy type I
JL Heraghty, TN Hilliard, A Majumdar, P Jardine, PJ Fleming, AJ Henderson
- P61** Impact of physiologist supervision on the quality of respiratory sleep studies in children
PL Davies, AJ Morley, P Jamieson, NA Gibson
- P62** Safety and validity of non-invasive methods of carbon dioxide monitoring in infants and young children
JL Heraghty, J James, V Rajkumar, AJ Henderson, H Evans
- P63** Respiratory data from pulse oximeter plethysmogram traces in acutely wheezy preschool children
C Olden, D Wertheim, E Symes, H Rabe, P Seddon
- P64** Intravenous therapy for acute asthma in children – what about the very young?
LE Wright
- P65** Are children with severe persistent allergic asthma receiving omalizumab, routinely prescribed an epinephrine auto-injector for use in the event of anaphylaxis?
M McFeeters, S Clayton, A Murphy
- P66** Omalizumab administered via injection does not prevent children with severe persistent allergic asthma from initiating or continuing with therapy
M McFeeters, S Clayton

SCIENTIFIC PROGRAMME

- P67** Advice on discharge after acute asthma
A Davenport, S Clayton, M Samuels
- P68** Primary tracheomalacia as a cause of persistent wheeze in cystic fibrosis during infancy
WT Walker, C Head, JP Legg, GJ Connett
- P69** Racial and ethnic variations in parental perceptions of asthma treatment
KN Ragubathy, T Ninan

4.15pm – 4.45pm

Churchill Auditorium, Ground floor

THE PRESIDENT'S ADDRESS

Transcending tribulations in training, transplantation and the Toon

Professor Paul Corris (Newcastle upon Tyne)

4.45pm – 5.00pm

Churchill Auditorium, Ground floor

Presentation of the BTS Medal

5.00pm – 5.30pm

Churchill Auditorium, Ground floor

BTS Annual General Meeting/Presentation of Trustees' Report and Accounts (BTS members only)

SCIENTIFIC PROGRAMME

8.00am – 9.00am

COFFEE/TEA will be served in the Whittle & Fleming Rooms, 3rd floor

8.45am – 4.00pm

Whittle & Fleming Rooms, 3rd floor

POSTER VIEWING

Authors present: 10.00am – 11.00am

P70–P81

Tuberculosis: epidemiology

Discussion of abstracts will take place from 1.45pm to 3.15pm in the St James's Suite, 4th floor

P82–P93

Understanding CF lung disease and its consequences

Discussion of abstracts will take place from 1.45pm to 3.15pm in the Henry Moore Room, 4th floor

P94–P107

COPD: exacerbations

Discussion of abstracts will take place from 2.00pm to 3.45pm in the Mountbatten Room, 6th floor

P108–P123

Screening and treatment of tuberculosis

Discussion of abstracts will take place from 3.30pm to 5.30pm in the St James's Suite, 4th floor

P124–P133

Clinical aspects of asthma

Discussion of abstracts will take place from 4.00pm to 5.15pm in the Westminster Suite, 4th floor

P134–P143

COPD: α 1-antitrypsin deficiency and other manifestations

Discussion of abstracts will take place from 4.00pm to 5.15pm in the Abbey Room, 4th floor

8.15am – 8.45am

Fleet Room, 2nd floor

THE BTS JOURNAL CLUB

Occupational lung disease

Dr David Fishwick (Sheffield)

8.30am – 10.00am

Westminster Suite, 4th floor

SPOKEN SESSION: S46 – S50

Airway challenges

Chaired by: Professor Neil Barnes (London) and Dr Graham Douglas (Aberdeen)

8.35am **S46**

Effects of allergen and trigger factor avoidance advice in primary care on asthma control – a randomized controlled trial

CA Bobb, T Ritz, G Rowlands, C Griffiths

8.50am **S47**

Disconnect between standardised field based testing and mannitol challenge in Scottish elite swimmers

KL Clearie, PA Williamson, S Vaidyanathan, P Short, A Goudie, BJ Lipworth

9.05am **S48**

The association between recent asthma medication and asthma death in a British case-control study

BK Butland, HR Anderson, CJ Cates

Thursday 3 December 2009

9.20am **S49** ABSTRACT WITHDRAWN

Severe asthma exacerbations in adults within the Symbicort SMART clinical trial programme, categorised according to BTS/SIGN treatment steps at study entry

J Gray, J Morais, O Östlund

9.35am **S50**

Inflammatory phenotypes of refractory asthma and the response to prednisolone

JB Morjaria, P Haldar, AJ Wardlaw, ID Pavord

8.30am – 10.00am

Elizabeth Windsor Room, 5th floor

SPOKEN SESSION: S51 – S55

NIV: clinical aspects

Chaired by: Dr Mark Elliott (Leeds) and Dr Nicholas Hart (London)

8.35am **S51**

A randomized trial of auto variable positive airway pressure versus standard non-invasive ventilation in COPD patients with chronic ventilatory failure

A Gulati, M Ali, N Osofrot, MG Davies, T Quinnell, JM Shneerson, IE Smith

8.50am **S52**

Activity levels at initiation of home mechanical ventilation (HMV) in patients with obesity hypoventilation syndrome (OHS)

P Murphy, K Brignall, M Hind, A Simonds, C Davidson, A Williams, J Moxham, M Polkey, N Hart

9.05am **S53**

Differentiation between hypercapnic obstructive sleep apnoea (OSA), combined OSA and obesity hypoventilation syndrome (OHS) and lone OHS in clinical practice

KK Lee, A Mistry, N Grey, P Murphy, AJ Williams, AC Davidson, N Hart

9.20am **S54**

Seasonal influenza – impact on NIV admissions and NIV failures (intubations and deaths)

G Walters, S Gill, B Beauchamp, E Gallagher, R Mukherjee, H Osman, D Banerjee

9.35am **S55**

Non-invasive ventilation in motor neurone disease: qualitative accounts of initiation and impact

LH Piggan, EW Thornton, RM Angus, B Chakrabarti, CA Young

8.30am – 10.15am

Churchill Auditorium, Ground floor

SYMPOSIUM

BTS/BTOG JOINT SYMPOSIUM: MESOTHELIOMA

Chaired by: Dr Martin Muers (Leeds) and Professor Ken O'Byrne (Dublin)

8.30am Current epidemiology of mesothelioma

Dr Robin Rudd (London)

8.45am New experimental approaches

Dr Daniel Stermann (Philadelphia)

9.15am Biomarkers

Professor YC Gary Lee (Perth)

9.45am Current treatment options (chemotherapy,

radiotherapy and surgery)

Mr John Edwards (Sheffield)

10.05am Medico-legal update

Dr Robin Rudd (London)

Thursday 3 December 2009

8.30am – 10.15am

St James's Suite, 4th floor

SYMPOSIUM

JOINT BTS/BPRS SYMPOSIUM: "LOST IN TRANSLATION?" THE CHALLENGES AND OPPORTUNITIES OF TRANSLATIONAL RESEARCH

Chaired by: Dr Andrew Fogarty (Nottingham) and Dr Alan Smyth (Nottingham)

8.30am What is translational research and how can it benefit patients?

Professor Sir Alex Markham (Leeds)

8.50am Fast track translation for cystic fibrosis

Dr Preston Campbell (Cystic Fibrosis Foundation, USA)

9.10am Fast track translation for children – the role of the Medicines for Children Research Network

Professor Ros Smyth (Liverpool)

9.30am "Dragons' Den" for translational research ideas

Dr David Harper (Biocontrol Ltd), Dr Richard Iles (Cambridge & PneumaCare) and Professor Adam Finn (Bristol)

8.30am – 10.15am

Henry Moore Room, 4th floor

SPOKEN SESSION: S56 – S61

Epidemiology of chronic respiratory disease

Chaired by: Dr Seif Shaheen (London) and Professor Graham Devereux (Aberdeen)

8.35am S56

Evidence for association between sarcoidosis and pulmonary embolism from 30-year record linkage study
AP Nataraja, CJ Wotton, MJ Goldacre, L-P Ho

8.50am S57

Increasing prevalence of spirometry-defined COPD in middle aged men and women in Scotland, 1995–2003
M Gillies, J Lewsey, H Starkie, A Briggs, M Shepherd, K MacIntyre

9.05am S58

Implications of screening for COPD: Results from the Burden of Obstructive Lung Disease (BOLD) study from 14 countries

A Jithoo, P Enright, WM Vollmer, S Gillespie, PGJ Burney

9.20am S59*

Is adult height related to the risk of having chronic obstructive pulmonary disease (COPD)?

K Ward*, R Hubbard

9.35am S60

Relationship between serum IgE levels, smoking and smoking cessation in an ageing population in the UK (the ELSA cohort)

J Fingleton, S Webster, N Rice, D Melzer, B Patel

9.50am S61

Explaining ethnic group differences in lung function: a cross-sectional study

R Hooper, MK Tumilty, JF Potts, PGJ Burney

*Winner, BTS Medical Student Abstract

SCIENTIFIC PROGRAMME

8.45am – 10.15am

Abbey Room, 4th floor

SPOKEN SESSION: S62 – S66

Innate immune responses to bacteria

Chaired by: Dr Anthony De Soyza (Newcastle upon Tyne) and Dr John Simpson (Edinburgh)

8.50am S62

Aberrant peripheral neutrophil migration in the healthy elderly as a potential cause of reduced bacterial clearance

E Sapey, N Aaronson, A Ahmad, H Chalal, RH Insall, JM Lord, RA Stockley

9.05am S63

The Streptococcus pneumoniae capsule protects against alveolar macrophage mediated early lung innate immunity

E Camberlein, CJ Hyams, JN Weiser, S Khandavilli, JM Cohen, JS Brown

9.20am S64

Previous colonisation protects against pneumococcal pneumonia: learning from natural immunity

S Khandavilli, E Camberlein, H Baxendale, J Brown, JM Cohen

9.35am S65

The Streptococcus pneumoniae capsule inhibits macrophage activation through the NF κ B and not MAPK activation pathways

CJ Hyams, E Camberlein, M Noursadeghi, JN Weiser, JS Brown

9.50am S66

Subversion of neutrophil apoptosis by Staphylococcus aureus: consequences for bacterial pathogenesis and host defence

S Anwar, I Sabroe, SJ Foster, MK Whyte

8.45am – 10.30am

Mountbatten Room, 6th floor

SYMPOSIUM

CLINICAL CONTROVERSIES IN CYSTIC FIBROSIS

Chaired by: Professor Stuart Elborn (Belfast) and Dr Helen Rodgers (Edinburgh)

8.45am Transplantation (including re-transplantation)

Dr Paul Aurora (London)

9.10am Clinical issues around an ageing CF population

Professor Stuart Elborn (Belfast)

9.35am Debate: In the advent of non-invasive ventilation (NIV) is there a place for intubation in CF?

Pro – Dr Ian Ketchell (Cardiff)

Con – Professor Tim Evans (London)

9.00am – 10.30am

Rutherford Room, 4th floor

SPOKEN SESSION: S67 – S71

Disease pathogenesis in interstitial lung disease

Chaired by: Dr Harold R Collard (San Francisco) and Professor Moira Whyte (Sheffield)

9.05am S67

A critical role for alternatively activated monocytes and macrophages in the pathogenesis of pulmonary fibrosis

MA Gibbons, AC MacKinnon, R Duffin, JP Iredale, T Sethi, SJ Forbes

SCIENTIFIC PROGRAMME

- 9.20am S68**
Murine haematopoietic stem cells but not murine mesenchymal stem cells ameliorate lung fibrosis using gene delivery of keratinocyte growth factor
K McNulty, S Aguilar, CJ Scotton, D Bonnet, SM Janes
- 9.35am S69**
Markers of systemic and endothelial inflammation among pigeon breeders
K Weir, C Rooney, A Hood, K Ruddock, I Donnelly, MR Adamson, SJ Bourke, C McSharry, K Anderson
- 9.50am S70**
Lysophosphatidic acid increases Itgb6 and Lpar2 Expression via TGF β -dependent and independent mechanisms
A Goodwin, J Porte, G Jenkins
- 10.05am S71**
Molecular mechanisms of lung epithelial cell injury induced by inhibition of Glutathione-S-Transferase (GST)
M Fletcher, P Boshier, RT Smolenski, PA Kirkham, H Keun, G Hanna, M Takata, N Marczin

10.00am – 11.00am

COFFEE/TEA will be served in the Whittle & Fleming Rooms and Benjamin Britten Lounge, 3rd floor

10.30am – 12.15pm Churchill Auditorium, Ground floor SYMPOSIUM

PLENARY SCIENTIFIC SYMPOSIUM

Chaired by: Professor Chris Haslett (Edinburgh) and Professor Michael Polkey (London)

- 10.30am** Mycobacteria
Dr Andres Floto (Cambridge)
- 10.55am** Epidemiology
Professor Peter Burney (London)
- 11.20am** Lung transplantation: maximising therapeutic impact
Professor Andrew Fisher (Newcastle upon Tyne)
- 11.45am** From molecular mechanisms to new therapies in pulmonary arterial hypertension
Professor Nicholas Morrell (Cambridge)

10.45am – 12.15pm Mountbatten Room, 6th floor SPOKEN SESSION: S72 – S76 Systemic aspects of COPD

Chaired by: Dr Roberto Rabinovich (Edinburgh) and Professor Wisia Wedzicha (London)

- 10.50am S72**
Quadriceps muscle expression of myostatin in COPD patients
WD Man, SA Sathyapala, J Riddoch-Contreras, A Lewis, G Marsh, MI Polkey, PR Kemp
- 11.05am S73**
Skeletal muscle gene expression in COPD patients with normal and low FFMI and healthy controls. A microarray gene expression analysis
RA Rabinovich, EM Drost, D Dunbar, J Manning, R Bastos, W MacNee

Thursday 3 December 2009

- 11.20am S74**
Lower-limb function and exercise performance in different MRC dyspnoea scale categories of COPD
MK Menon, L Houchen, SJ Singh, MD Morgan, MC Steiner
- 11.35am S75**
Pulmonary rehabilitation improves cardiovascular risk factors in patients with COPD
NS Gale, JM Duckers, D Proud, T Lines, S Enright, JR Cockcroft, DJ Shale, CE Bolton
- 11.50am S76**
Extrapulmonary polypharmacy and cardiovascular medications in COPD
ARC Patel, S Karmali, JJP Goldring, GC Donaldson, JK Quint, JR Hurst, JA Wedzicha

12.15pm – 2.00pm

LUNCH will be available to purchase in the Cafe in the Pickwick Suite, 1st floor, and the Snack Bar in the Whittle & Fleming Rooms, 3rd floor

12.30pm – 1.15pm Churchill Auditorium, Ground floor THE BTS LECTURE Steroid resistance in COPD and severe asthma and how it may be reversed

Professor Peter Barnes (London)

Introduced by: Professor Michael Morgan (Leicester)

1.45pm – 3.15pm Elizabeth Windsor Room, 5th floor SYMPOSIUM BTS/BLF/BALR YOUNG INVESTIGATORS SYMPOSIUM

Chaired by: Professor Nicholas Morrell (Cambridge) and Professor Michael Polkey (London)

Judging panel: Professor Andrew Fisher (Newcastle upon Tyne), Dr Kim Harrison (Swansea) and Professor Richard Hubbard (Nottingham)

- 1.45pm T1**
Simvastatin reduces inflammation and improves clinical outcomes in ALL: results of the HARP study
TR Craig, MJ Duffy, M Shyamsundar, C O' Kane, JS Elborn, DF McAuley
- 2.00pm T2**
Endothelial progenitor cells are dysfunctional in pulmonary hypertension
M Toshner, M Southwood, R Al-Lamki, LS Howard, A Exley, S Stewart, J Pepke-Zaba, N Morrell
- 2.15pm T3**
EP4 receptor mediated PGE2 inhibition of Akt phosphorylation sensitizes fibrotic lung fibroblasts to FasL-induced apoptosis
TM Maher, IC Evans, GJ Laurent, RJ McNulty
- 2.30pm T4**
Vitamin D binding protein and alveolar macrophage activation: a mechanism for the vitamin D axis in lung disease
AM Wood, DR Thickett, CR Bassford, P Rajesh, RA Stockley

SCIENTIFIC PROGRAMME**Thursday 3 December 2009****2.45pm T5**

Establishing the pulmonary transit time of primed and unprimed neutrophils in man
C Summers, JF White, NR Singh, IM Mackenzie, A Johnston, KK Balan, C Solanki, AM Peters, ER Chilvers

3.00pm T6

Do differences exist between nasal and bronchial in-vitro epithelium in non-asthmatic and asthmatic children?
S Thavagnanam, JC Parker, G Skibinski, LG Heaney, MD Shields

1.45pm – 3.15pm**St James's Suite, 4th floor****POSTER DISCUSSION: P70 – P81****Tuberculosis: epidemiology**

Chaired by: *Dr Ian Campbell (Cardiff) and Dr Ben Marshall (Southampton)*

- P70** Ethnic differences in vitamin D levels amongst patients with tuberculosis (TB) in south-east London
JK Randhawa, V Kahr, FA Post, RD Barker, HJ Milburn
- P71** Find&Treat – tough times in the TB capital of Europe
A Story, S Hemming, M Lipman
- P72** Find&Treat – returning the lost back to local TB Services
A Story, P Windish, J Hall, M Lipman
- P73** The changing epidemiology of tuberculosis in Central Manchester
S Singhanian, C Bell, M Woodhead
- P74** Clinical epidemiology of tuberculosis (TB) in Somalis in south-east London
VP Kahr, JK Randhawa, FA Post, LV Baker, TC Stokes, HJ Milburn, RD Barker
- P75** Screening prisoners for TB – what should the UK do?
S Yates, A Story, AC Hayward
- P76** Tuberculosis in London and other English cities: is the capital the special one?
ME Kruijshaar, I Abubakar, JP Crofts, M Lipman
- P77** Inconsistent and incoherent? Methods of screening new-entrants for tuberculosis in the United Kingdom
M Pareek, I Abubakar, PJ White, GP Garnett, A Lalvani
- P78** Screening patients initiating anti-TNF agents for mycobacterial infection using IGRA: the experience of a large inflammatory bowel disease service
K Greveson, C Murray, C Toumpanakis, L Baptista, I Cropley, M Hamilton, M Lipman
- P79** TB-ST Rapid Test for tuberculosis diagnosis: does it hold promise?
N Javanshir, D Shah, J Ivanyi, HJ Milburn
- P80** How useful are IGRAs in cases of suspected tuberculosis?
HSR Hosker, J Anderson, A Crabtree, P Godwin
- P81** A comparison between interferon-gamma release assays and the tuberculin skin test in the diagnosis of tuberculosis in patients with renal disease
DW Connell, R Charif, N Duncan, C McCrudden, E Harden, S Seneviratne, OM Kon

1.45pm – 3.15pm**Henry Moore Room, 4th floor****POSTER DISCUSSION: P82 – P93****Understanding CF lung disease and its consequences**

Chaired by: *Professor Andrew Greening (Edinburgh) and Miss Valerie Hall (Belfast)*

- P82** Effect of a rational cross-infection control policy on the spread of a transmissible *Pseudomonas aeruginosa* strain
A Ashish, M Shaw, TS Jordan, E Spencer, HG Tan, A Collins, B Govin, M Ledson, MJ Walshaw
- P83** Increasing resistance of the Liverpool epidemic strain of *Pseudomonas aeruginosa* (LES) to antibiotics in CF – a cause for concern?
A Ashish, J Mcshane, T.S Jordan, HG Tan, A Collins, E Spencer, C Cowperthwaite, M Ledson, MJ Walshaw
- P84** Reticular basement membrane thickening in end-stage cystic fibrosis lung disease
M Brodli, MC McKean, GE Johnson, AJ Fisher, PA Corris, JL Lordan, C Ward
- P85** Success and utility of sputum induction in non-expectorating CF subjects: data from the UK CF gene therapy run-in study
NWG Voase, G Davies, PA Reid, KA Macleod, MH Dewar, NJ Bell, C Saunders, AP Greening, S Cunningham, JA Innes, EFWF Alton, JC Davies
- P86** Exploring the phenotype of the lymphocytic infiltrate in the CF airway: do IL-17+ cells play a role in disease pathogenesis?
H Tan, N Regamey, T Hilliard, E Alton, A Bush, CM Lloyd, JC Davies
- P87** Survey on the utilisation of non-invasive ventilation (NIV) in UK and Australasian children with cystic fibrosis (CF)
A Gupta, N Collins, S Wright, L Gauld, A Bush, DS Urquhart
- P88** Can cystic fibrosis shared care work?
S Quinn, R Buchdahl, A Bush
- P89** Recurrent severe haemoptysis in cystic fibrosis
FMR Perrin, S Padley, KM Gyi, D Bilton, ME Hodson
- P90** Relationship between HbA1c and lung disease in patients with cystic fibrosis not known to have diabetes
SA Srivastava, JC Burgess, KM Gyi, ME Hodson, D Bilton, EH Baker
- P91** Chronic respiratory diseases strongly influence major life changing decisions
ZU Bhatti, AY Finlay, S Salek, RI Ketchell, CE Bolton
- P92** Mean 3 day glucose is closely linked to HbA1c in adults with CF
JM Helm, R Rowe, AL Brennan, AM Jones, AK Webb
- P93** Association of nocturnal hypoxia and clinical status in childhood cystic fibrosis (CF)
DS Urquhart, S Stanojevic, A Laverty, D Odendaal, G Derrick, E Scrase, M Bryon, JE Williams, H Montgomery, I Narang, A Jaffé

SCIENTIFIC PROGRAMME

2.00pm – 3.30pm

Rutherford Room, 4th floor

SPOKEN SESSION: S77 – S81

Asthma: basic mechanisms

Chaired by: Professor Peter Bradding (Leicester) and Professor Alan Knox (Nottingham)

2.05pm **S77**

ELISPOT evaluation of PBMC responses to *Staphylococcus aureus*
J Perera, B Green, M Arden-Jones, P Howarth

2.20pm **S78**

Interleukin-5 induces glucocorticoid resistance in human eosinophils
S Brode, N Farahi, AS Cowburn, JK Juss, AM Condliffe, ER Chilvers

2.35pm **S79**

α V β 5-mediated TGF- β activation by airway smooth muscle cells in asthma
AL Tatler, L Jolly, J Porte, C Brightling, AJ Knox, L Pang, G Jenkins

2.50pm **S80**

Screening for novel anti-inflammatory therapies in a whole animal in vivo model
AL Robertson, CA Loynes, MK Whyte, SA Renshaw

3.05pm **S81**

A comparison of two methods to quantify Tenascin C expression within the reticular basement membrane of paediatric endobronchial biopsies
R O' Reilly, N Ullmann, J Zhu, A Bush, PK Jeffery, S Saglani

2.00pm – 3.45pm

Churchill Auditorium, Ground floor

SYMPOSIUM

ACUTE LUNG INJURY

Chaired by: Professor Rachel Chambers (London) and Dr Mark Griffiths (London)

2.00pm Clinical overview of acute lung injury

Dr Mark Griffiths (London)

2.15pm Pathogenesis of ARDS

Dr David Thickett (Birmingham)

2.45pm Human models of lung inflammation

Dr Daniel McAuley (Belfast)

3.15pm Pressure guided mechanical ventilation to reduce ALI

Dr Stephen Loring (Boston)

2.00pm – 3.45pm

Westminster Suite, 4th floor

SPOKEN SESSION: S82 – S87

New observations from physiology

Chaired by: Dr Nicholas Hopkinson (London) and Professor Mike Hughes (London)

2.05pm **S82**

Clinical usefulness of measuring neural respiratory drive (NRD) for identification of deterioration in acute exacerbations of COPD
P Murphy, A Kumar, C Reilly, C Jolley, K Brignall, M Polkey, J Moxham, N Hart

Thursday 3 December 2009

2.20pm **S83**

Face mask spirometry in patients with Bulbar Motor Neurone disease
AA Khaliq, IE Smith

2.35pm **S84**

Quadriceps endurance is reduced in fibrotic idiopathic interstitial pneumonia
L Mendoza, A Gogali, D Shrikrishna, SV Kemp, AS Jackson, ZF Shaikh, MI Polkey, AU Wells, NS Hopkinson

2.50pm **S85**

Comparison of ear and finger oximetry readings during ambulatory oxygen assessments
E Barnett, R Barraclough, A Duck

3.05pm **S86**

The effect of acute hypoxia on QT interval in respiratory patients undergoing fitness to fly tests
JRA Skipworth, DA Raptis, Z Puthuchery, J Rawal, D Shrikrishna, J Windsor, D Cramer, MI Polkey, HE Montgomery, NS Hopkinson

3.20pm **S87**

Shallow breathing and cyst-like spaces augment deadspace ventilation in coalworkers pneumoconiosis
Dr J Cotes, Dr J Reed, Dr DW Wilson

2.00pm – 3.45pm

Mountbatten Room, 6th floor

POSTER DISCUSSION: P94 – P107

COPD exacerbations

Chaired by: Dr Richard Russell (Slough) and Dr Tom Wilkinson (Southampton)

P94

Use and utility of a 24-hour informed telephone support service for 'high risk' patients with COPD
JR Hurst, F Fitzgerald-Khan, JJP Goldring, JK Quint, JP Dilworth, C Mikelsons, JA Wedzicha

P95

The effect of telephone weather alert system on emergency COPD admissions and health care utilisation in patients with mild to moderate airflow obstruction
N Diar Bakerly, A Thompson, JA Roberts

P96

Effect of an innovative automated interactive health forecast alert system on rate of exacerbations of COPD

D Halpin, T Laing-Morton, M Levy, P Marno

P97

Geographical influence on reporting COPD exacerbations

PJ Rudd, GC Donaldson, JK Quint, JP Goldring, JR Hurst, JA Wedzicha

P98

A retrospective analysis of predictors of mortality and re-admission after an exacerbation of COPD

A Fahim, W Lee, S Faruqi, JA Kastelik

P99

Changes in plasma cotinine at exacerbation, and faster exacerbation recovery in non-smokers, in COPD

GC Donaldson, JK Quint, D Powrie, R West, JA Wedzicha

P100

Sputum bacteriology in acute exacerbation of COPD: utility of sputum appearance and previous culture results in determining antibiotic therapy

W Shafiq, G Antunes, S Murphy

P101

Vitamin D levels and susceptibility to human rhinovirus exacerbations of COPD

JK Quint, GC Donaldson, JJP Goldring, A Patel, S Karmali, N Wassef, M Thomas, JA Wedzicha

Thursday 3 December 2009

- P102** Concurrent COPD/pneumonia: incidence and clinical outcomes amongst patients admitted with exacerbation
N Ahmad, S George, E Davis, KS Srinivasan, H Moudgil
- P103** Biological, physiological and subjective biomarkers in COPD subjects at stable state and exacerbation: an observation
M Bafadhel, S Terry, S McKenna, V Mistry, C Reid, M McCormick, P Rugman, P Dodson, M Saunders, ID Pavord, CE Brightling
- P104** Serum procalcitonin and C-reactive protein in patients hospitalised with pneumonia, asthma or chronic obstructive pulmonary disease (COPD)
T Clark, M Bafadhel, C Reid, M Medina, M Barer, K Nicholson, CE Brightling
- P105** Effect of a case management study on primary care use and prescribing for AECOPD
SM Jones, P Albert, CJ Warburton, PMA Calverley, L Davies
- P106** Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease
K Perrin, M Wijesinghe, B Healy, M Weatherall, R Beasley
- P107** Inflammatory profile of COPD exacerbations associated with dual bacterial isolates
JJP Goldring, GC Donaldson, JK Quint, R Baghai-Ravary, ARC Patel, JA Wedzicha

3.15pm – 4.15pm

COFFEE/TEA will be served in the Whittle & Fleming Rooms and Benjamin Britten Lounge, 3rd floor

3.30pm – 5.15pm

Henry Moore Room, 4th floor

SPOKEN SESSION: S88 – S93

In-vivo and in-vitro modelling in acute lung injury

Chaired by: Professor Edwin Chilvers (Cambridge) and Dr Cecilia O’Kane (Belfast)

3.35pm S88

Sources of increased plasma soluble TNF receptors during injurious mechanical ventilation in mice
AD Dorr, MR Wilson, KP O’Dea, M Takata

3.50pm S89

Epithelial to mesenchymal transition in an in vitro model of acute respiratory distress syndrome
CM O’Kane, V d’Sousa, DR Thickett, DF McAuley

4.05pm S90

ROS-dependent activation of p38 MAPK is required for LPS-induced upregulation of TNF-alpha converting enzyme (TACE/ADAM-17) activity on primary human monocytes
AJ Scott, KP O’Dea, JM Handy, M Takata

4.20pm S91

Role of intravascular leukocytes in ventilator-induced lung injury in the isolated perfused mouse lung
K Wakabayashi, MR Wilson, KP O’Dea, M Takata

4.35pm S92

Differential activation of the P38 MAP kinase pathway in mouse monocyte subsets during coculture with pulmonary endothelial cells
JO Dokpesi, KP O’Dea, M Takata

SCIENTIFIC PROGRAMME

4.50pm S93

Influence of cardiac surgery utilising cardiopulmonary bypass on neutrophil-related pro-inflammatory responses
EF Goode, LR Hector, AL Lagan, DD Melley, GJ Quinlan, RE Bundy

3.30pm – 5.30pm

St James’s Suite, 4th floor

POSTER DISCUSSION: P108 – P123

Screening and treatment of tuberculosis

Chaired by: Ms Alyson Anderton (Nottingham) and Dr Jack Barker (London)

P108 The National Multi Drug Resistant TB Service
PDO Davies, DM Cullen

P109 Treatment interruptions and inconsistent supply of anti-tuberculosis drugs in the UK: a national review
TGD Capstick, D Laycock, MCI Lipman, on behalf of the UK Coalition to Stop TB

P110 Does a specialist TB nurse service improve outcome?
R King, MJ Carter, SB Mungall, MR Hetzel

P111 Who gets directly observed therapy? Use of a risk management tool to identify TB patients at greatest need
SM Dart, C Snook, M Lipman

P112 No impact of HIV co-infection on the frequency of adverse events in patients treated for active tuberculosis – a prospective study
RAM Breen, CJ Smith, FM Perrin, MA Johnson, I Cropley, MCI Lipman

P113 Assessment of risk factors for mild adverse drug reactions to standard anti-tuberculous therapy and affects on compliance
WM Ricketts, WO Pickrell, M Parikh, RB Banka

P114 Chemoprophylaxis following an outbreak of isoniazid resistant tuberculosis in a community school: compliance and tolerance in an adolescent population to a regime of rifampicin and ethambutol
JM Brown, N Boparai, M Brown, P Gothard, S Morris-Jones, D Shingadia, S Anaraki, H Booth

P115 Safety of moxifloxacin when used to treat active tuberculosis in patients at risk of hepatotoxicity
CH Roberts, R Gadhok, R Breen, M Murphy, C Smith, I Cropley, S Bhagani, S Hopkins, M Lipman

P116 The utility of early morning urine(EMU) culture in the diagnosis of tuberculosis
R Sathyamurthy, R Jones, J Kavi, AB Rajasekaran

P117 Clinical utility of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for the diagnosis of mediastinal tuberculous lymphadenitis
PL Molyneaux, K Muttardi, DW Connell, M Wickremasinghe, A Lalvani, A Jepson, J McCarthy, C Wright, OM Kon

P118 A role for 2-[fluorine 18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) scanning in active tuberculosis
F Shora, G Cook, J Lewis, A Lalvani, M Wickremasinghe, OM Kon

SCIENTIFIC PROGRAMME

- P119** Challenging current practice can increase microbiological diagnosis of tuberculosis from surgically acquired samples
DI Thomas, MB Jarvis, AJ Williams
- P120** What is "active" in active tuberculosis?
RAM Breen, R Shorten, CJ Smith, C Cash, J Cleverley, T McHugh, S Gillespie, MCI Lipman
- P121** Prolonged infectivity in urban UK TB patients: an underappreciated problem?
DW Connell, R Nathavitharana, A Jepson, D Deeab, R Dhawan, M O'Donoghue, P Molyneaux, A Lalvani, OM Kon
- P122** TB contact tracing at a school in a low incidence area
B Pankhania, C Thompson, K Nash, B Marshall, S Cotterill, S Faust
- P123** A survey of DOT provision in London
S Hemming, S Tamne, J Hall, A Story

4.00pm – 5.15pm

Westminster Suite, 4th floor

POSTER DISCUSSION: P124 – P133

Clinical aspects of asthma

Chaired by: Professor Fan Chung (London) and Dr Andrew Menzies-Gow (London)

- P124** Reproducibility of the Multiple Breath Nitrogen Washout (MBNW) test in healthy volunteers and mild–moderate asthmatic subjects
MF Biddiscombe, S Verbanck, S Meah, PJ Barnes, OS Usmani
- P125** Is upper airway wheeze ("vocal cord dysfunction") the missing link in the association between GORD and asthma?
CE Bucknall, GA Miller, P Vaughn
- P126** Obesity and theophylline use are associated with GORD in a problem asthma cohort
GA Miller, CE Bucknall
- P127** Importance of comorbid conditions in patients attending a problem asthma clinic
GA Miller, CE Bucknall
- P128** Correlations identified between sputum eosinophils and pulmonary function in patients with severe refractory asthma
A Lu, G Tavernier, JA Sloan, C Prys-Picard, RM Niven
- P129** Omalizumab reduces maintenance oral corticosteroid use in patients with severe persistent allergic asthma
R Niven, M Molimard, R Buhl, V Le Gros, A Thielen, J Thirlwell, R Maykut
- P130** Risk factors for frequent exacerbations and airflow obstruction in severe asthma
S Shah, S Gupta, M Bafadhel, A Singapuri, P Haldar, W Monteiro, ID Pavord, AJ Wardlaw, CE Brightling
- P131** Modelling the impact of inhaled drug particle size of salbutamol on bronchodilator response using artificial intelligence
M de Matas, Q Shao, M Biddiscombe, H Chrystyn, PJ Barnes, OS Usmani
- P132** In vitro validation of radiolabelled inhaled corticosteroid for in vivo lung delivery using gamma scintigraphy
MF Biddiscombe, S Meah, R Sadler, PJ Barnes, OS Usmani

Thursday 3 December 2009

- P133** The implications of not well-controlled asthma. UK results from a European survey
J Foo, L Rice, K Annunziata, GD Castillo

4.00pm – 5.15pm

Abbey Room, 4th floor

POSTER DISCUSSION: P134 – P143

COPD: α 1-antitrypsin deficiency and other manifestations

Chaired by: Dr Ravi Mahadeva (Cambridge) and Professor Robert Stockley (Birmingham)

- P134** Polymicrobial airway colonisation and systemic inflammation in stable COPD
JJP Goldring, GC Donaldson, JK Quint, R Baghai-Ravary, ARC Patel, JA Wedzicha
- P135** Assessment of osteoporosis risk in COPD patients, a community based study
Y Shanshal, EL Wooff, M Foster, L Swift, T Burns, J Ward
- P136** Does severity of chronic obstructive pulmonary disease determine the risk of depression?
R Yadavilli, I Webster
- P137** Reduced expression and activity of myocardin related transcription factors contributes to fibre type changes in the quadriceps of patients with COPD
A Lewis, SA Sathyapala, J Riddoch-Contreras, WDC Man, GS Marsh, MI Polkey, NS Hopkinson, PR Kemp
- P138** Multiple-frequency bioelectrical impedance analysis and quadriceps strength in COPD patients
D Shrikrishna, JL Kelly, L Mendoza, AS Jackson, SV Kemp, V Lord, MI Polkey, NS Hopkinson
- P139** Relationships between comorbidities, exacerbation frequency and FEV1 in COPD
ARC Patel, S Karmali, JJP Goldring, JK Quint, GC Donaldson, JR Hurst, JA Wedzicha
- P140** Increased arterial stiffness in patients with α 1-antitrypsin deficiency
JM Duckers, DJ Shale, NS Gale, JR Cockcroft, RA Stockley, CE Bolton
- P141** Bone mineral density and fat free mass in patients with α 1-antitrypsin deficiency
JM Duckers, DJ Shale, NS Gale, BA Evans, WD Fraser, RA Stockley, CE Bolton
- P142** Polymers of Z α 1-antitrypsin are induced by pulmonary inflammation
S Alam, Z Li, S Janciauskiene, R Mahadeva
- P143** The role of muscarinic receptors in regulation of neutrophilic chemokine release from human lung macrophages
J Renshaw, P Fenwick, C Thomas, L Donnelly

4.00pm – 5.30pm

Elizabeth Windsor Room, 5th floor

SPOKEN SESSION: S94 – S98

Cystic fibrosis from top to bottom

Chaired by: Dr David Honeybourne (Birmingham) and Dr Charles Haworth (Cambridge)

- 4.05pm S94** Cystic fibrosis newborn screening: the case for invasive surveillance after diagnosis
P Staffler, JC Davies, IM Balfour-Lynn, M Rosenthal, A Bush

Thursday 3 December 2009

4.20pm S95

Effect of exercise on large artery haemodynamics in cystic fibrosis
JH Hull, L Ansley, CE Bolton, JE Sharman, RK Knight, JR Cockcroft, DJ Shale, R Garrod

4.35pm S96

Gastro-oesophageal reflux and cough in cystic fibrosis patients
JE McCreanor, ID Molyneux, S Faruqi, W Jackson, J O'Donnell, P Sedman, AH Morice

4.50pm S97

Assessment of diaphragm fatigue following high intensity exercise in patients with cystic fibrosis
C Reilly, K Ward, L Frank, C Jolley, A Lunt, J Steier, C Elston, GF Rafferty, J Moxham

5.05pm S98

The use and perceived benefits of non-invasive ventilation for hypercapnic cystic fibrosis adults in a regional centre
J Barrett, P Agostini, S Cameron, E Nash, J Whitehouse, D Honeybourne

4.00pm – 5.45pm Churchill Auditorium, Ground floor

SYMPOSIUM

EXPLORING THE NEXT GENERATION OF LUNG IMAGING MODALITIES

Chaired by: Professor Chris Haslett (Edinburgh) and Dr Sylvia Worthy (Newcastle upon Tyne)

4.00pm Lung optical imaging
Dr Kev Dhaliwal (Edinburgh)

4.25pm Is there a future for CT?
Dr Sujal Desai (London)

4.50pm Uses of non-cancer PET lung imaging
Dr Hazel Jones (London)

5.15pm Functional MRI in lung disease
Dr Jim Wild (Sheffield)

4.00pm – 6.00pm Mountbatten Room, 6th floor

SYMPOSIUM

'LATE BREAKING NEWS' SYMPOSIUM – THE MANAGEMENT OF EMPYEMA IN 2010

Chaired by: Professor Duncan Geddes (London) and Professor YC Gary Lee (Perth)

4.00pm The BTS pleural disease guidelines
Dr Nicholas Maskell (Bristol)

4.30pm The MIST 2 trial
Dr Naj Rahman (Oxford)

A1 Primary result of the 2nd Multi-centre Intrapleural Sepsis (MIST2) trial; randomised trial of intrapleural tPA and DNase in pleural infection.
NM Rahman, N Maskell, CWH Davies, A West, R Teoh, A Arnold, D Peckham, N Ali, A Bentley, CI Mackinlay, WJ Kinnear, JM Wrightson, HE Davies, RF Miller, YCG Lee, EL Hedley, N Crosthwaite, L Choo, J Darbyshire, FV Gleeson, AJ Nunn, RJO Davies

5.00pm Medical and surgical perspectives
Professor Robert Davies (Oxford) and Professor John Dark (Newcastle upon Tyne)

SCIENTIFIC PROGRAMME

6.00pm – 7.30pm

Benjamin Britten Lounge, 3rd floor

THE PRESIDENT'S RECEPTION – YOUNG INVESTIGATORS, MEDICAL STUDENT AND IMPRESS AWARD PRESENTATIONS

SCIENTIFIC PROGRAMME

8.00am – 9.00am

COFFEE/TEA will be served in the Whittle & Fleming Rooms, 3rd floor

8.45am – 2.00pm

Whittle & Fleming Rooms, 3rd floor

POSTER VIEWING

Authors present: 10.00am – 11.00am

P144–P157

Managing a sleep disorder service

Discussion of abstracts will take place from 1.30pm to 2.30pm in the Westminster Suite, 4th floor

P158–P173

Lung cancer: practice and epidemiology

Discussion of abstracts will take place from 1.30pm to 3.00pm in the St James's Suite, 4th floor

P174–P184

Causes and consequences of chronic cough

Discussion of abstracts will take place from 1.30pm to 3.00pm in the Henry Moore Room, 4th floor

P185–P194

COPD: identification and testing

Discussion of abstracts will take place from 1.30pm to 2.45pm in the Abbey Room, 4th floor

P195–P210

Education and training

Discussion of abstracts will take place from 2.00pm to 4.00pm in the Rutherford Room, 4th floor

P211–P218

Evaluating interventions in COPD

Discussion of abstracts will take place from 3.00pm to 4.00pm in the Abbey Room, 4th floor

P219–P227

Clinical implications of lung infection

Discussion of abstracts will take place from 2.00pm to 3.15pm in the Elizabeth Windsor Room, 5th floor

8.15am – 8.45am

Fleet Room, 2nd floor

THE BTS JOURNAL CLUB

Lung cancer

Professor Tariq Sethi (Edinburgh)

8.30am – 10.15am

Churchill Auditorium, Ground floor

SYMPOSIUM

MICROBES AND HOST-DEFENCE IN LUNG DISEASE

Chaired by: Professor Edwin Chilvers (Cambridge) and Professor Sebastian Johnston (London)

8.30am Molecular microbiology – what foes are likely to be disclosed by new technologies

Professor William Cookson (London)

8.55am Clinical manifestations and innate responses in fungal infections of the lung

Professor David Denning (Manchester)

9.20am How the lungs fight bacterial respiratory infection

Dr Jeremy Brown (London)

9.45am How the lungs fight respiratory viral infection

Professor Peter Openshaw (London)

Friday 4 December 2009

8.30am – 10.15am

Westminster Suite, 4th floor

SPOKEN SESSION: S99 – S104

New techniques in diagnosis and treatment of respiratory diseases

Chaired by: Dr Philip Ind (London) and Dr Mohammed Munavvar (Preston)

8.35am S99

Comparison of the measurement of bronchodilator response in asthmatics and healthy volunteers using spirometry and impulse oscillometry

JH Ward, A Nair, BJ Lipworth

8.50am S100

Comparison of forced expiratory volumes measured with structured light plethysmography and pneumatach spirometry

E Lau, DH Brand, JA Usher-Smith, R Wareham, J Cameron, P Bridge, W Hills, G Roberts, R Iles, J Lasenby

9.05am S101

Measurement of tidal breathing: a comparison of structured light plethysmography with pneumatachography

DH Brand, E Lau, JA Usher-Smith, R Wareham, J Cameron, P Bridge, W Hills, G Roberts, J Lasenby, R Iles

9.20am S102

Evaluating bronchoalveolar lavage cellular profiles using flow cytometry in patients with pulmonary and systemic disease

ARC Patel, S Jamal, K Kumar, S Lear, M Lowdell, F Tahami, M Beckles, R Chee, MCI Lipman

9.35am S103

Combining EBUS-TBNA with standard bronchoscopic techniques for the diagnosis of pulmonary sarcoidosis

N Navani, HL Booth, B Sheinman, N Johnson, S Janes

9.50am S104

Experience of a tertiary centre with removable self-expandable metal stents

J Alçada, N Navani, HL Booth, SM Janes, J George

8.30am – 10.15am

Mountbatten Room, 6th floor

SPOKEN SESSION: S105 – S110

COPD: cells and genes

Chaired by: Professor Ian Pavord (Leicester) and Dr Duncan Rogers (London)

8.35am S105

Fibrinopeptide A α 360: a footprint of neutrophil elastase activity

R Carter, R Mumford, K Treonze, R Stockley

8.50am S106

Diesel exhaust particles potentiate inflammation and render it resistant to IL-1 antagonism in vitro

N Chaudhuri, LC Parker, I Sabroe, K Donaldson

9.05am S107

Inhaled corticosteroids (ICS) in airway remodelling in COPD

A Soltani, S Sohal, D Reid, HK Muller, S Weston, R Wood-Baker, EH Walters

Friday 4 December 2009

9.20am S108

Decreased macrophage function in COPD
CMR Thomas, MA Saunders, JA Wedzicha, PJ Barnes, LE Donnelly

9.35am S109

Morphometric comparison of airway remodelling in chronic obstructive pulmonary disease (COPD) and obliterative bronchiolitis (OB)
LA Borthwick, CL Pate, LS Mackay, GE Johnson, PA Corris, J Majo, AJ Fisher

9.50am S110

Autoimmunity associated genetic polymorphisms in chronic obstructive pulmonary disease
AM Wood, RA Stockley

8.45am – 10.30am

Abbey Room, 4th floor

SPOKEN SESSION: S111 – S116

Pathways of vascular remodelling in PAH

Chaired by: Professor Nicholas Morrell (Cambridge) and Dr Robert Naeije (Brussels)

8.50am S111

Bone morphogenetic protein (BMP)-9 increases endothelin (ET)-1 release by human pulmonary artery endothelial cells via a MAPK dependent pathway
JES Park, PD Upton, PM de Souza, RJ Davies, NW Morrell, MJD Griffiths, SJ Wort

9.05am S112

Pulmonary vascular remodelling in a mouse model of schistosomiasis
A Crosby, FM Jones, M Southwood, S Stewart, R Schermuly, G Butrous, DW Dunne, NW Morrell

9.20am S113

BMP9 suppresses MCP1 production by human pulmonary artery endothelial cells
PD Upton, JES Park, RJ Davies, M Griffiths, SJ Wort, PM De Souza, NW Morrell

9.35am S114

Mechanical strain at the pulmonary microvasculature induces monocyte chemoattractant protein-1 (MCP-1) which contributes to pulmonary inflammation and remodelling in chronic heart failure
JES Park, AR Lyon, LR Hector, MJD Griffiths

9.50am S115

Osteoprotegerin /tumor necrosis factor related apoptosis-inducing ligand pathway: a potential biomarker for pulmonary arterial hypertension
R Condliffe, AG Hameed, C Paiva, J Suntharalingam, SE Francis, CMH Newman, DC Crossman, NW Morrell, A Lawrie

10.05am S116

Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type-II
HJ Durrington, P Upton, T Criley, B Dunmore, S Hoer, PJ Lehner, J Boname, L Butler, D Blackbourne, NW Morrell

10.00am – 11.00am

COFFEE/TEA will be served in the Whittle & Fleming Rooms and Benjamin Britten Lounge, 3rd floor

SCIENTIFIC PROGRAMME

10.30am – 12.15pm

Churchill Auditorium, Ground floor

SYMPOSIUM

JOINT BTS/BSACI SYMPOSIUM: NEW HORIZONS IN ASTHMA

Chaired by: Dr Gerard Cox (Hamilton) and Professor Sebastian Johnston (London)

10.30am Measuring asthma severity and control
Professor Martyn Partridge (London)

10.55am Phenotyping asthma: what are the phenotypes?
Professor Chris Brightling (Leicester)

11.20am Severe asthma: what are we learning?
Professor Fan Chung (London)

11.45am A new approach: rationale and results of bronchial thermoplasty
Dr Gerard Cox (Hamilton)

10.30am – 12.15pm

Mountbatten Room, 6th floor

SYMPOSIUM

UKRRC SYMPOSIUM: INFRASTRUCTURE AND CAREER PATHWAYS

Chaired by: Professor Stephen Holgate (Southampton) and Professor Sir Anthony Newman Taylor (London)

10.30am The NIHR CRN: how does it work for me?
Professor Peter Calverley (Liverpool)

11.00am An update on NIHR
Professor Dame Sally Davies (Department of Health)

11.30am The evolution of respiratory medicine
Professor Stephen Holgate (Southampton)

10.30am – 12.15pm

Westminster Suite, 4th floor

SPOKEN SESSION: S117 – S122

Molecular frontiers in lung cancer diagnosis and treatment

Chaired by: Dr Sam Janes (London) and Professor Tariq Sethi (Edinburgh)

10.35am S117

EGFR and KRAS mutation analysis by endobronchial ultrasound guided transbronchial needle aspiration in NSCLC
G Santis, R Breen, A Quinn, E McLean, K Tobal

10.50am S118

Chemokine receptor expression in tumour islets and stroma in non-small cell lung cancer
CM Ohri, A Shikotra, RH Green, DA Waller, P Bradding

11.05am S119

Differences in profiles of volatile organic compounds (VOCs) in the breath of lung cancer patients versus controls
KE Lewis, CO Philips, H Shukla, R Ghosal, PJ Kloer, JG Mullins, T Claypole

11.20am S120

Tumour necrosis factor α expression in tumour islets confers a survival advantage in non-small cell lung cancer
CM Ohri, A Shikotra, RH Green, DA Waller, P Bradding

SCIENTIFIC PROGRAMME

Friday 4 December 2009

11.35am S121

Clinical implementation of a 84-gene-signature predicting early recurrence after resection for NSCLC
BM Muehling, H Kestler, KH Holzmann, L Sunder-Plassmann

11.50am S122

Delivery of magnetic nanoparticles by mesenchymal stem cells for hyperthermic treatment of lung cancer
MR Loebinger, PG Kyratatos, MF Lythgoe, P Southern, M Kallumadil, AN Price, QA Pankhurst, SM Janes

10.30am – 12.15pm

St James's Suite, 4th floor

SPOKEN SESSION: S123 – S128

Getting ahead in lung infection

Chaired by: *Dr Diana Bilton (London) and Dr Wei Shen Lim (Nottingham)*

10.35am S123

Procalcitonin (PCT) identifies acute heart failure patients in need of antibiotic therapy: observational results from the BACH (Biomarkers in Acute Heart failure) trial

O Hartmann, J Landsberg, C Mueller, R Nowak, P Ponikowski, M Moeckel, C Hogan, AHB Wu, M Richards, GS Filippatos, S Di Somma, IS Anand, L Ng, SX Neath, R Christenson, J McCord, NG Morgenthaler, R Engineer, A Bergmann, SD Anker, AS Maisel, FW Peacock

10.50am S124

A meta-analysis of severity scores for predicting ITU admission in patients admitted with community acquired pneumonia

P Mandal, AR Akram, G Choudhury, C Lucas, P Short, C Scally, L Leitch, A Singanayagam, JD Chalmers, AT Hill

11.05am S125

Long term nebulised gentamicin in non-cystic fibrosis bronchiectasis improves microbial load, exercise tolerance, exacerbation frequency and health related quality of life

MP Murray, JRW Govan, CJ Doherty, AP Greening, RD Gray, AJ Simpson, C Haslett, TS Wilkinson, JD Chalmers, AT Hill

11.20am S126

Molecular detection of complex microbial communities in sputa of patients with cystic fibrosis and non-CF bronchiectasis

R Duff, N Simmonds, P Pantelidis, R Wilson, J Davies, E Alton, W Cookson, M Moffat, D Bilton

11.35am S127

Randomized controlled trial of high concentration versus titrated oxygen therapy in community-acquired pneumonia

M Wijesinghe, K Perrin, R Beasley

11.50am S128

Acute kidney injury on admission independently predicts need for dialysis and 30-day mortality in patients with pneumonia.

AR Akram, A Singanayagam, G Chowdhury, P Mandal, JD Chalmers, AT Hill

10.45am – 12.30pm

Elizabeth Windsor Room, 5th floor

SPOKEN SESSION: S129 – S134

COPD: counting the costs

Chaired by: *Professor Michael Pearson (Liverpool) and Dr Robert Winter (Cambridge)*

10.50am S129

Length of stay as an indicator of the efficiency of hospital care for COPD

G Tack, PP Walker, E Thompson, H Crone, G Flatt, MG Pearson

11.05am S130

Use of 30 day mortality after inpatient admission as a quality marker of COPD care

PP Walker, G Tack, E Thompson, H Crone, G Flatt, MG Pearson

11.20am S131

Use of proportion of COPD patients admitted under a respiratory specialist as a marker of COPD care

E Thompson, PP Walker, G Tack, H Crone, G Flatt, MG Pearson

11.35am S132

Could the average "total bed days per patient" be an indicator of combined hospital and community care?

G Tack, PP Walker, E Thompson, H Crone, G Flatt, MG Pearson

11.50am S133

Joined up thinking-concept of a lung/rheumatology MDT in a DGH setting

P Huey, C Adams, Y Ahmed, DJ McKeon

12.05pm S134

A story with no beginning and an ill-defined end: a serial qualitative study of end-stage COPD

HJ Pinnock, M Kendall, A Worth, A Sheikh, M Porter, W MacNee, P Levack, S Murray

10.45am – 12.15pm

Abbey Room, 4th floor

SPOKEN SESSION: S135 – S139

Thoracic surgery and transplantation

Chaired by: *Dr Martin Carby (Uxbridge) and Professor John Dark (Newcastle upon Tyne)*

10.50am S135

10 year survival for routine lung cancer resection by a minimal invasive anterior approach: comparison to open standard thoracotomy

R Stanbridge, SL Elkin, A Suliman, A Chuckwuemeka, S Roberts, T Athanasiou

11.05am S136

Identifying risk factors for rescue mini-tracheostomy – should patients with COPD and/or over the age of 75 undergoing lung resection receive one prophylactically?

P Agostini, H Cieslik, S Rathinam, E Bishay, M Kalkat, R Steyn, P Rajesh, B Naidu

11.20am S137

Debridement alone without decortication can achieve lung re-expansion in patients with empyema: an observational study

P Kho, J Karunanatham, M Leung, E Lim

Friday 4 December 2009

11.35am S138

Recovery of calcineurin inhibitor related nephrotoxicity with Sirolimus after lung transplantation
S Kon, C Orchard, A Palmer, M Carby

11.50am S139

An audit of surveillance bronchoscopy in lung transplant recipients
S Agarwal, J Parmar, S Tsui, J Dunning, K Dhital

12.15pm – 2.00pm

LUNCH will be available to purchase in the Cafe in the Pickwick Suite, 1st floor, and the Snack Bar in the Whittle & Fleming Rooms, 3rd floor

12.30pm – 1.15pm

Churchill Auditorium, Ground floor
THE MORAN CAMPBELL LECTURE

Hypo-inflation

Professor Neil Pride (London)

Introduced by: Professor Michael Polkey (London)

1.15pm – 2.45pm

Mountbatten Room, 6th floor
SPOKEN SESSION: S140 – S144

Managing the airway defect in cystic fibrosis

Chaired by: Dr Eric Alton (London) and Dr Alastair Innes (Edinburgh)

1.20pm S140

Towards gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes
U Griesenbach, K Mitomo, M Inoue, L Somerton, C Meng, T Tabata, Y Ueda, G Frankel, R Farley, C Singh, M Chan, F Munkonge, A Brum, S Xenariou, S Escudero-Garcia, M Hasegawa, EFWF Alton

1.35pm S141

Evaluation of safety and gene expression with a single dose of pGM169/GL67A administered to the nose and lung of individuals with cystic fibrosis: the UK CF Gene Therapy Consortium 'Pilot Study'
JC Davies, G Davies, N Voase, S Hyde, A Innes, C Boyd, D Porteous, T Higgins, U Griesenbach, D Gill, EFWF Alton

1.50pm S142

Ceramide is increased and associated with neutrophilic inflammation in the lower airway epithelium of people with cystic fibrosis
M Brodli, MC McKean, GE Johnson, AJ Fisher, PA Corris, JL Lordan, C Ward

2.05pm S143

Increased incidence of cystic fibrosis related diabetes in patients infected with transmissible *Pseudomonas aeruginosa* strains
A Ashish, M Shaw, TS Jordan, H.G Tan, E Spencer, A Collins, P Dyce, J Daniels, M Ledson, MJ Walshaw

2.20pm S144

Bronchoalveolar lavage in children with cystic fibrosis: which lobe is best?
FJ Gilchrist, S Salamat, S Clayton, J Peach, J Alexander, W Lenney

SCIENTIFIC PROGRAMME

1.30pm – 2.30pm

Westminster Suite, 4th floor

POSTER DISCUSSION: P144 – P157

Managing a sleep disorder service

Chaired by: Dr Martin Allen (Stoke on Trent) and Dr Brendan Cooper (Birmingham)

P144

Health related quality of life in obesity hypoventilation syndrome (OHS) prior to initiation of home mechanical ventilation (HMV)

P Murphy, K Brignall, A Williams, C Davidson, M Hind, A Simonds, J Moxham, M Polkey, N Hart

P145

The effects of hyperoxia in obesity hypoventilation syndrome

M Wijesinghe, K Perrin, R Beasley

P146

Is there a role for routine sleep and respiratory assessment as part of the pre-operative work up of patients being assessed for bariatric surgery?

S Blankley, O Orhan, C Hammond, D Heath, P Sufi, L Restrict

P147

A study of obstructive sleep apnoea in patients who have undergone bariatric surgery

HJ Ramsey, CW le Roux, J Cousins, AR Ahmed, ARC Cummin, MR Partridge

P148

Has the body mass index of the population referred for investigation of obstructive sleep apnoea changed over an eight year period?

JS Cosgrove, A Fogarty, VJ Cooper, R Holt, T Bewick

P149

Can continuous positive airway pressure (CPAP) cause a change in body mass index (BMI)?

A Collins, G Phillipson, S Huq, A de Ramon

P150

Rates of known depressive illness in people attending a sleep disordered breathing clinic

L Davies, B Sekar, J Bhat, KE Lewis

P151

Prevalence of symptomatic obstructive sleep apnoea (OSA) and nocturnal hypoxic load in adult sickle cell disease (SCD)

P Murphy, R Dillon, S Higgins, K Brignall, A Williams, C Davidson, J Howard, N Hart

P152

Screening for obstructive sleep apnoea syndrome in a cardiac prevention and rehabilitation programme

R Ghiassi, PO'Neill, J Edwards, A Cummin, S Connolly, MR Partridge

P153

Is the new service specification for investigation and treatment of obstructive sleep apnoea syndrome (March 2009) an appropriate commissioning tool?

SJ Capocci, S Furneaux, L Ward, F Eltaie, DJ Powrie, AG Davison

P154

Setting up a sleep apnoea service post NICE: our experiences

S Isse, Z Mangera, F Woodhead, C Mabuto, I Basharet, J Samuels

P155

CPAP therapy in obstructive sleep apnoea-hypopnoea syndrome (OSAHS) – is routine annual clinic review necessary?

WG Flight, P McMackin, S Mehdi, B Turnpenny, N Corlett, H Nangle, C Houghton, DC Weir

P156

Clinical severity stratification and continuous positive airway pressure response in OSAHS: what are the influencing factors?

S Huq, G Phillipson, R Grainger, A de Ramon

SCIENTIFIC PROGRAMME

- P157** Predictors of obstructive sleep apnoea hypopnoea syndrome in attenders to a sleep disordered breathing clinic
L Davies, B Sekar, J Bhat, KE Lewis

1.30pm – 3.00pm

St James's Suite, 4th floor

POSTER DISCUSSION: P158 – P173

Lung cancer: practice and epidemiology

Chaired by: *Dr Michael Peake (Leicester) and Professor Stephen Spiro (London)*

- P158** Does variation in completeness of data entry to LUCADA affect the treatment offered to patients with lung cancer?
AL Rich, LJ Tata, RA Stanley, DR Baldwin, RB Hubbard
- P159** Can we improve adjuvant chemotherapy uptake in the management of resected lung cancer? An audit of practice across the Mid Trent Lung Cancer Network
AM Binnion, C Lynch, GM Cox
- P160** Mesothelioma in the National Lung Cancer Audit
P Beckett, I Woolhouse, R Stanley, MD Peake
- P161** The impact of implementing a local cancer awareness campaign on referrals to secondary care for suspected lung cancer
B Kane, M Simpson, R Sundar
- P162** Influence of case-mix adjustment on outcomes in the National Lung Cancer Audit
IS Woolhouse, P Beckett, RA Stanley, MD Peake
- P163** An analysis of significant event audits of lung cancer diagnosis in primary care
E Mitchell, U Macleod, G Rubin
- P164** UK national survey on radiologist's perspective of lung cancer MDT- can we do better?
A Aujayeb, A Shariff, L Talbot, L Huntley, S Bari
- P165** Survival in stage III primary non small cell lung cancer (NSCLC) following radical surgery
M Wilczynska, P Haldar, J Bennett, D Yilmaz
- P166** Why do lung cancer patients not receive first choice treatment? An in-depth local analysis of National Lung Cancer Audit data
A Oldroyd, Y Khan, C Choo, I Woolhouse
- P167** Does an incidental finding of lung cancer on CTPA have a better outcome than lung cancer found by an alternative approach?
RWCR Robbins, SI Iles, G Maskell
- P168** Improving the lung cancer pathway – a one year audit of CT evaluation of equivocal CXRs
O Kirmi, E Woo, T Meagher, A Prasad, D Taylor
- P169** Survival of patients with brain metastases and non-small cell lung cancer (NSCLC)
JK Randhawa, SP Patel, TC Stokes
- P170** Use of Experian MOSAIC to explore variability in process and outcomes in lung cancer patients
L Chishimba, J Morris, M Dudgon, P Beckett
- P171** Use of chemotherapy in NSCLC in the National Lung Cancer Audit
P Beckett, I Woolhouse, R Stanley, A Yelland, MD Peake
- P172** Changing histopathology of resected lung cancer
KG Carter, L Callaghan, DR Miller, JS Mclay, KM Kerr, SJ Watt

Friday 4 December 2009

- P173** The National Lung Cancer Audit – year 4 completeness and outcomes
P Beckett, I Woolhouse, R Stanley, MD Peake

1.30pm – 3.00pm

Henry Moore Room, 4th floor

POSTER DISCUSSION: P174 – P184

Causes and consequences of chronic cough

Chaired by: *Dr Surinder Birring (London) and Professor Alyn Morice (Hull)*

- P174** Repeatability of objective cough frequency in acute cough
K Singer, H Sumner, W Powley, R Murdoch, A Woodcock, JA Smith, A Kelsall
- P175** Acute cough: measurement of QOL with the Leicester Cough Questionnaire (LCQ)
N Yousaf, B Jayaraman, ID Pavord, SS Birring
- P176** Factors affecting cough frequency in a mixed population
N Yousaf, S Matos, SS Birring, ID Pavord
- P177** The cough hypersensitivity syndrome: a distinct clinical entity
AH Morice, S Faruqi, CE Wright, R Thompson, JM Bland
- P178** Description of the urge-to-cough in chronic cough
AT Thurston, E Young, P Marsden, S Decalmer, A Woodcock, JA Smith
- P179** The assessment of cough in patients with IPF and sarcoidosis
AS Patel, D Cox, G Rafferty, T Fleming, L Morgan, C Wood, SS Birring
- P180** Patient registration of cough during oesophageal monitoring
RP Francis, A Kelsall, K McGuinness, S Decalmer, H Jones, A Woodcock, L Houghton, J Smith
- P181** Poor adherence to BTS recommendations for the management of cough in adults
S Khalid, R Beckett, W Malik, P Marsden, A Morice, L McGarvey, J Smith
- P182** Does it matter how we breathe? Perceptions in normal subjects when adopting different routes of breathing
AJ Williams, A Pitcher, P Thomas, R Baker
- P183** Gamma scintigraphy: regions of interest in the lungs – are we being consistent in what we are measuring?
MF Biddiscombe, S Meah, PJ Barnes, OS Usmani
- P184** High prevalence of urinary incontinence in adult bronchiectasis patients
J Rees, HM Tedd, A De Soyza

1.30pm – 2.45pm

Abbey Room, 4th floor

POSTER DISCUSSION: P185 – P194

COPD: identification and testing

Chaired by: *Dr Lisa Davies (Liverpool) and Professor Dennis Shale (Cardiff)*

- P185** The British Lung Foundation's search for the "missing millions" of COPD patients
I Jarrold, N Eiser, K Leach, T Lethbridge
- P186** Who and where are the "missing millions" of COPD patients in the UK?
I Jarrold, N Eiser, J Morrell

Friday 4 December 2009

- P187** Defining 'symptomatic' in COPD patients: a national study
J Upton, E McCutcheon, C Loveridge, J Wiggins, S Walker, M Fletcher
- P188** Precision in diagnosing and classifying COPD: comparison of historical height with current height and arm span to predict FEV1
K Ansari, A Kay, IK Taylor, J Munby, NP Keaney
- P189** COPD and chronic bronchitis risk of solid fuel smoke: a systematic review and meta-analysis
O Kurmi, S Semple, PP Simkhada, WCS Smith, JG Ayres
- P190** Comparison between patients with and without airways obstruction from the Sheffield COPD study: implications for population screening
AC Darby, JC Waterhouse, C Young, M Aziz, J Wight, CG Billings, C Billings, V Stevens, CM Burton, CM Barber, D Morgan, PD Blanc, D Fishwick
- P191** COPD in Sheffield; how do case definitions of COPD effect risk estimates for causative factors?
AC Darby, JC Waterhouse, CM Barber, CM Burton, J Wight, PD Blanc, V Stevens, C Billings, CG Billings, D Fishwick
- P192*** Evaluation of performing spirometry in cardiology outpatients
DM Neville, SMS Smith, SL Elkin*
- P193** An empirical analysis of the 2008 National COPD Audit
N Nzekwue, S Bremner, S Taylor, N Pursey, M Roberts, R Stone
- P194** Effect of GOLD stage on rate of decline in gas transfer and spirometry in COPD
JL Kelly, P Mehta, D Shrikrishna, D Cramer, MI Polkey, NS Hopkinson

*Highly Commended, BTS Medical Student Abstract

1.45pm – 3.45pm Churchill Auditorium, Ground floor

SYMPOSIUM

THE CARDIOPULMONARY RESPONSE TO HYPOXIA: LESSONS FROM ALTITUDE AND PATIENTS WITH LUNG DISEASE

Chaired by: *Dr Robert Naeije (Brussels) and Professor Andrew Peacock (Glasgow)*

- 1.45pm** PH secondary to hypoxic lung disease: overview
Dr Joan Barbera (Barcelona)
- 2.15pm** The role of hypoxia: gas exchange at extreme altitude
Professor Michael Grocott (London)
- 2.45pm** Right ventricular function in PH associated with altitude and chronic lung disease
Dr Robert Naeije (Brussels)
- 3.15pm** Should patients with lung disease associated pulmonary hypertension be given PH targeted therapy?
Dr David Kiely (Sheffield)

2.00pm – 4.00pm Rutherford Room, 4th floor POSTER DISCUSSION: P195 – P210

Education and training

Chaired by: *Dr Tim Howes (Colchester) and Professor Martyn Partridge (London)*

- P195** Thoracic ultrasound: competency and training strategies within our region
LM Jones, AB Hardy, J Hogg

SCIENTIFIC PROGRAMME

- P196** Has training following the NPSA alert improved the safety of Seldinger chest drain insertion?
CM Hallsworth, H Walters, CWH Davies, GV Robinson
- P197** Attaining Level I chest ultrasound competency: progress of the delegates who attended the Basic Thoracic Ultrasound Skills for Chest Physicians course (2005 to 2009)
AR Guhan, S Kluzek, A Saha, J Fletcher, A Babu, G Naisby
- P198** Chest drain insertion training using simulation – West Midlands Deanery Module
T R Naicker, C Dave, M Menon, DT McLeod
- P199** Collaboration between researchers and patients in development of a COPD research programme
JW Dodd, H Persaud, JRH Archer, SA Srivastava, PW Jones, EH Baker
- P200** The assessment of psychosocial problems and disability in COPD patients in primary care
J Upton, C Loveridge, M Fletcher
- P201** Use of a simple questionnaire to measure knowledge of oxygen prescribing at induction for the FI year
P C Deegan
- P202** Oxygen prescribing in a district general hospital: an audit, re-audit after educational sessions and modified oxygen prescription proforma
ML Harley, AJ Wickham, RG Francis, JA Hughes
- P203** An audit of the effect of oxygen prescription charts on clinical practice
M Wijesinghe, K Perrin, R Beasley
- P204** Consultant led specialist community COPD clinic ... does it work?
N Diar Bakerly, JA Roberts
- P205** BTS Bronchoscopy Training Survey 2009
IA Du Rand, RA Lewis
- P206** Self management in asthma and COPD
I Younis, NJ Roberts, MR Partridge
- P207** Declining respiratory clinical academics – a model for reversing the trend?
OS Usmani, EM Watson, SN Meah, ME Hodson, JA Mitchell
- P208** UK respiratory trainees' views about implementing e-learning into postgraduate training
SF Smith, NJ Roberts, MR Partridge
- P209** Can doctors correctly identify the correct site for chest drain insertion?
JL Gallagher, N Stevenson
- P210** Was the NPSA alert about chest drains justified?
TPRN Brown, WA Fayed, PJ Andrews, DE Laws

2.00pm – 3.15pm Elizabeth Windsor Room, 5th floor POSTER DISCUSSION: P219 – P227

Clinical implications of lung infection

Chaired by: *Dr Jeremy Brown (London) and Professor Margaret Hodson (London)*

- P219** Attempted eradication of *Pseudomonas aeruginosa* in non-cystic fibrosis bronchiectasis with oral ciprofloxacin monotherapy
A Jones, J Stowell, M Nizbet, R Wilson
- P220** Systemic manifestations of bronchiectasis
NS Gale, JM Duckers, M Munnerly, S Enright, JR Cockcroft, CE Bolton, DJ Shale

SCIENTIFIC PROGRAMME**Friday 4 December 2009**

- P221** Streptococcus pneumoniae infection: enhanced prediction of survival beyond pneumonia severity scoring
L Varatharajan, A Draper, S Akhtar, A Higton, K Gajee, F Chua
- P222** Pro-inflammatory potential of Pseudomonas aeruginosa in macrophage models; importance of clinical origin?
LA Borthwick, J Perry, AJ Fisher, A De Soyza, SS Sunny
- P223** The effects of temperature and humidity on adult admissions with community acquired pneumonia
J Micallef, R Callus, J Mamo, S Montefort
- P224** Reasons for hospitalisation in patients with community acquired pneumonia with low CURB65 scores and their outcome
G Choudhury, JD Chalmers, P Mandal, AR Akram, MP Murray, PM Short, A Singanayagam, AT Hill
- P225** Antibiotics for exacerbations of non CF bronchiectasis: when, why and what do respiratory physicians prescribe and for how long?
JG Macfarlane, AT Hill
- P226** Development of an adult 'Cystic Fibrosis Swine Flu Triage Service' in a London tertiary referral centre
DJ Dhasmana, K Dack, K Gyi, ME Hodson, D Bilton
- P227** Procalcitonin – a useful marker of systemic bacterial sepsis?
Veeresh Patil, JB Morjaria, F DeVilliers, KS Babu

3.00pm – 4.00pm**Abbey Room, 4th floor****POSTER DISCUSSION: P211 – P218****Evaluating interventions in COPD**

Chaired by: Mrs Karen Heslop (Newcastle upon Tyne) and Dr David Singh (Manchester)

- P211** Safety and tolerance of nebulised ADC4022 (low-dose theophylline) in healthy volunteers and COPD patients
S Snape, JC Fox, MF Fitzgerald, NJC Snell
- P212** Fast onset of effect of acclidinium bromide, a novel, long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease
J Vestbo, C Vogelmeier, J Creemers, A Ribera, E Garcia Gil
- P213** A Phase III study evaluating acclidinium bromide, a novel long-acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I
PW Jones, P Chanez, A Agusti, H Magnussen, L Fabbri, C Caracta, E Garcia Gil
- P214** Is review in the chest clinic or GP surgery advantageous: clues from the 2008 UK COPD Audit
RA Stone, JM Potter, D Lowe, NA Pursey, RJ Buckingham, CM Roberts
- P215** Microbial contamination of home nebulisers used by COPD patients
S Jarvis, RJ Shiner, CP Thomas, S Goonesekera, R Haffenden, A Abdolrasouli, PW Ind
- P216** Attitudes of clinical staff towards inpatient oxygen prescribing
D Nazareth, K Nguyen, H Tan, P Deegan
- P217** Improved heart rate variability after long-term oxygen therapy in hypoxic patients with COPD
KE Lewis, JA Annandale, MJ Lewis

- P218** The accuracy of oxygen flow meters in a secondary respiratory service (wards and high dependency units) at a London hospital
PI Suppiah, SMS Smith, SE Elkin

3.00pm – 4.30pm**Mountbatten Room, 6th floor****SPOKEN SESSION: S145 – S149****Is it asthma or not?**

Chaired by: Dr Gerard Cox (Ontario) and Dr Robert Niven (Manchester)

3.05pm S145

High concentration oxygen causes carbon dioxide retention in severe asthma: a randomised controlled trial

*K Perrin, M Wijesinghe, M Weatherall, R Beasley***3.20pm S146**

Airways dysfunction and eosinophilic inflammation in elite athletes with symptoms suggesting exercise induced asthma

*N Martin, MR Lindley, B Hargadon, W Monteiro, ID Pavord***3.35pm S147**

Hypertonic saline challenge in the diagnosis of vocal cord dysfunction in asthmatics attending a secondary care clinic

*VK Reay, I Susnerwala, RB Gore, J Haines, SJ Fowler***3.50pm S148**

Diagnosis of vocal cord dysfunction in asthma with high resolution dynamic volume computerised tomography of the larynx

*PW Holmes, KK Lau, M Crossett, GS Hamilton, PG Bardin***4.05pm S149**

Exposure to occupational agents and risk of asthma in the 1958 birth cohort from age 16 to age 33 years

*R Ghosh, P Cullinan, D Strachan, D Fishwick, J Hoyle, C Warburton, D Jarvis, R Hooper***3.00pm – 4.30pm****COFFEE/TEA will be served in the Benjamin Britten Lounge, 3rd floor**

SPEAKERS' BIOGRAPHICAL DETAILS

Dr Ibrahim Abubakar is a Consultant Epidemiologist and heads the TB Section at the HPA Centre for Infections. He holds a substantive Clinical Senior Lecturer post at the University of East Anglia and is an Honorary Senior Lecturer at the London School of Hygiene and Tropical Medicine and at University College London. Dr Abubakar runs the national enhanced TB surveillance system and is responsible for a national clinical/public health advisory service in support of TB incident/outbreak management. He is a member of the WHO Global Task Force on TB Impact Measurement and acting chair of the National Knowledge Service TB. He qualified in medicine and subsequently trained in general medicine and infectious disease epidemiology. Dr Abubakar's academic public health training was undertaken at the London School of Hygiene and Tropical Medicine, the University of Cambridge and the University of East Anglia. His current research interests include various aspects of the epidemiology and control of mycobacterial infections.

Dr Paul Aurora is Consultant in Paediatric Respiratory Medicine and Lung Transplantation at Great Ormond Street (GOS) Hospital for Children and Honorary Senior Lecturer at the UCL Institute of Child Health. He has been a Consultant at GOS since 2002, where he primarily works in tertiary paediatric respiratory medicine, but also has additional duties in lung transplantation, and some duties in cardiac transplantation. Dr Aurora is academic lead for respiratory medicine at GOS, and clinical lead for paediatric respiratory physiology. He helped set up the International Paediatric Lung Transplant Collaboration, and is currently Assistant Director of the Registry of the International Society for Heart and Lung Transplantation, and the paediatric co-chair of the ATS/ISHLT/ERS working group for standards of care for lung transplant recipients. He was involved with a joint ERS/ATS working group to establish standards for lung function testing in preschool children, chairing the spirometry section, and is currently chair of the ERS Scientific Group on Paediatric Respiratory Physiology. In 2002, Dr Aurora received the European Respiratory Society Award for Paediatric Research in Europe.

Professor Peter Barnes is Professor of Thoracic Medicine at the National Heart and Lung Institute, Head of Respiratory Medicine at Imperial College and Honorary Consultant Physician at Royal Brompton Hospital, London. He qualified at Cambridge and Oxford Universities and was appointed to his present post in 1987. He has published over 1000 peer-review papers on asthma, COPD and related topics and has edited over 40 books. He is also amongst the top 50 most highly cited researchers in the world and has been the most highly cited clinical scientist in the UK and the most highly cited respiratory researcher in the world over the last 20 years. Professor Barnes was elected a Fellow of the Royal Society in 2007, the first respiratory researcher for over 150 years. He is currently a member of the Scientific Committee of the WHO/NIH global guidelines on asthma (GINA) and COPD (GOLD). He also serves on the Editorial Board of over 30 journals and is currently an Associate Editor of *Chest* and respiratory Editor of *PLoS Medicine*. He has given several prestigious lectures, including the Amberson Lecture at the American Thoracic Society and the Sadoul Lecture at the European Respiratory Society.

Dr Colin Bingle is currently a Senior Lecturer in the Academic Unit of Respiratory Medicine at the University of Sheffield. His long-standing research interests are in cellular differentiation and

regulation of gene expression within the pulmonary epithelium and innate immunity and host defence. His work has a particular emphasis on the identification and characterisation of novel proteins using molecular, bioinformatic and comparative biological approaches.

Professor Tim Birkhead is an Evolutionary Biologist interested in behaviour and reproduction, conservation and the history of science, and he is a Fellow of the Royal Society. Much of his research is on the reproductive biology of birds. Professor Birkhead has published over 200 papers in refereed journals, 11 books and numerous articles in popular magazines. He writes a monthly column in the *Times Higher Education*. Professor Birkhead has a strong commitment to public understanding of science (Café Scientifique, book festivals, public speaking, radio and TV interviews). Recent books include 'Promiscuity' (2000) and 'The Wisdom of Birds' (Bloomsbury 2008).

Dr Charlotte Bolton is Senior Lecturer in Respiratory Medicine at the University of Nottingham. Her main research interests are COPD, in particular the systemic complications, and also pulmonary rehabilitation.

Professor Chris Brightling is a Wellcome Senior Clinical Fellow and Honorary Consultant Respiratory Physician at Glenfield Hospital in Leicester. He has published over 100 peer-reviewed papers. His research is focussed on understanding the pathophysiology and improving the clinical management of airway disease. In particular he has major interests in the utilisation of inflammatory markers in the management of airway diseases and the role of mast cell-airway smooth muscle interactions in asthma. He is a member of the BTS/SIGN guideline committee, the ATS/ERS severe asthma guideline group and the WHO severe asthma strategy group. He is an associate editor for *Chest* and is on the editorial board of other specialist respiratory journals.

Dr Jeremy Brown is a clinician scientist and a Reader in Respiratory Infection in the Centre for Respiratory Research at UCL. His main research interest is the molecular pathogenesis of *Streptococcus pneumoniae* pneumonia, and his clinical interests are pneumonia, infections in the immunocompromised host and bronchiectasis.

Professor Peter Burney is Professor of Respiratory Epidemiology and Public Health Medicine at Imperial College, London, and has been the Honorary Director of the Department of Health's Social Medicine and Health Services Research Programme since 1996. His interests are mainly in the epidemiology of asthma and COPD and he co-chairs the Global Burden of Disease group on chronic respiratory disease.

Professor Peter Calverley graduated from the University of Edinburgh in 1973 and completed his clinical and research training in Scotland and Montreal. He moved to Liverpool in 1985 and became Professor of Respiratory Medicine there in 1995. His major research interests have been in the clinical management of COPD and its physiological basis. He is currently an Associate Editor of *Thorax* and chairs the science committee of the GOLD initiative. He was a co-chair of the Department of Health group developing the clinical strategy for COPD and currently chairs the UKCLRN respiratory research sub-group.

Dr Preston W Campbell III is Executive Vice President for Medical Affairs, the Cystic Fibrosis Foundation. He earned his MD degree from the University of Virginia Medical School where he first became interested in cystic fibrosis as a CF camp counsellor during the summer months. He was a Pediatric resident and Chief resident at Vanderbilt University School of Medicine. He then earned a diploma from the Liverpool (England) School of Tropical Medicine and became Director of the Department of Pediatrics at the Centre Medical Beraca, LaPointe, Haiti for two years. Dr Campbell subsequently returned to Vanderbilt to join the faculty and complete his Pediatric Pulmonology training. As an Associate Professor of Pediatrics he served as the Center Director of the Cystic Fibrosis (CF) Center and as the Medical Director of the Adolescent Unit. He was active in both basic science and clinical research.

In 1998, Dr Campbell joined the CF Foundation as the executive vice president for medical affairs in order to leverage his efforts and join an already exciting medical-scientific program. His role has changed dramatically since 1998 as the focus of the CF Foundation has turned to drug discovery and development. In addition to drug discovery and development, Dr Campbell is responsible for overseeing clinical research, the CF Foundation's network of specialty care centers, training programs and other medical components of the CF Foundation, including the national patient registry database

Dr Campbell has received numerous awards, including recognition in *The Best Doctors in America*, Naifeh and Smith (eds.) Woodward and White, first edition (1992–93), second edition (1994–95), third edition (1999–2000), fourth edition (2001–2002), fifth edition (2003–2004), sixth edition (2005–2006) and seventh edition (2007–2008) for *Pediatric Pulmonology*. He has a large number of research grants, lectures and published articles to his credit. In addition to his responsibilities at the CF Foundation, Dr Campbell continues to see patients once a week at The Johns Hopkins Hospital in Baltimore.

Professor Rachel Chambers leads a team of basic and clinical scientists located in the Centre for Respiratory Research at University College London (UCL). Her research interests are centred on the elucidation of the pathomechanisms leading to lung inflammation and fibrosis, with a particular focus on the role of procoagulant signalling pathways following acute and chronic lung injury. Professor Chambers' research programme is conducted according to an integrated physiological approach and encompasses studies performed using *in vitro* and *in vivo* model systems and translational studies in patient-derived tissues and primary cells. She is Postgraduate Tutor for the Division of Medicine at UCL and is on the Editorial Board of *the American Journal of Respiratory Cell and Molecular Biology*. Her research is funded by major peer-reviewed grants awarded by the Wellcome Trust, the MRC, the British Lung Foundation and the European Union.

Professor Edwin Chilvers is Professor of Respiratory Medicine at the University of Cambridge and Honorary Consultant Physician at Addenbrooke's Hospital, CUHNHSFT and Papworth Hospital NHSFT. His research interests include understanding the molecular basis of neutrophil priming, activation and apoptosis, in particular, the role of the phosphoinositide 3-kinases and the use of radiolabelled autologous granulocytes to define neutrophil kinetics *in vivo*.

SPEAKERS' BIOGRAPHICAL DETAILS

Professor Fan Chung is Professor of Respiratory Medicine at the National Heart and Lung Institute, Imperial College London and Honorary Consultant Physician at the Royal Brompton and Harefield NHS Trust, London. His research interests include oxidative stress mechanisms, corticosteroid insensitivity and airway smooth muscle biology in relation to asthma and COPD.

Dr Jonathan R Codd is currently employed as a Lecturer in Integrative Vertebrate Biology within the Faculty of Life Sciences at The University of Manchester. His current clinical interests centre on adaptations in the pulmonary surfactant system in response to temperature challenge in mammals. Dr Codd's general research interests focus on further elucidating the role of constraints (be they internal or external) during locomotion and respiration in birds and mammals.

Dr Harold R Collard is Assistant Professor of Medicine in the Division of Pulmonary and Critical Care Medicine at the University of California, San Francisco and Director of the UCSF Interstitial Lung Disease Program. Dr Collard received his undergraduate degree from Harvard College and his medical degree from Duke University. He completed his internship, residency and chief residency in Internal Medicine at UCSF, and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado.

Professor Bill Cookson is Professor of Genomic Medicine and Director of Respiratory Science at Imperial College London. Over the past 20 years, the group he leads with Miriam Moffatt, have found many genetic effects on asthma. They are now applying genomic technologies to other respiratory diseases, including lung cancer and respiratory infections (metagenomics).

Professor Paul A Corris is Professor of Thoracic Medicine in the Institute of Cellular Medicine at Newcastle University and Regional Cardiothoracic Centre, Freeman Hospital. He is Director of the Pulmonary Vascular Service and Director of Cardiopulmonary Transplantation in Newcastle. He is a Past President of the International Society of Heart and Lung Transplantation and is President Elect of the British Thoracic Society. He has held several positions within the BTS including Chairman of the Scientific Committee, where he chaired the programme committee and is currently a member of Executive and Council. He is BTS representative on the SAC. He is a member of the Toon Army.

Dr Gerard Cox trained at the University of Iowa with Dr Gary Hunninghake, and currently is Professor of Medicine at McMaster University, Hamilton, Canada. He is Past Chair of the Canadian Thoracic Society. His research interests are in pulmonary responses to injury and inflammation.

Professor Paul Cullinan is Professor in Occupational and Environmental Respiratory Disease, Department of Occupational and Environmental Medicine, Imperial College (National Heart and Lung Institute), London and Honorary Consultant, Respiratory Medicine, Royal Brompton Hospital, London. His academic interests are the epidemiology of occupational lung diseases, and in particular of occupational asthma, and other environmental determinants of lung disease.

SPEAKERS' BIOGRAPHICAL DETAILS

Professor Adnan Custovic is a Professor of Allergy and Head of Respiratory Research Group at the School of Translational Medicine, University of Manchester. His professional training consisted of specialist training in Paediatrics and successive appointments as Clinical Research Fellow and Specialist Registrar in Allergy. This period saw him awarded MSc (1991), MD with Gold Medal (1996) and PhD (2000). His academic work focuses principally on the gene and environment interactions in the development of allergic diseases and primary prevention of asthma. Professor Custovic has authored or co-authored more than 100 articles in the major medical journals and contributed with chapters to a number of major textbooks. He has given more than 100 invited lectures at the major national and international congresses. At national level Professor Custovic serves as Secretary of the BSACI (2009–2011). At an international level, he serves as Chairman of the Asthma Section of the European Academy of Allergy and Clinical Immunology (EAACI). Professor Custovic is a member of the Executive Committees of ARIA and GARD.

Professor Dame Sally Davies is the Director General (DG) of Research and Development and Chief Scientific Adviser for the Department of Health and NHS. As DG she developed the new government research strategy, *Best Research for Best Health* with a budget rising to £1 billion, and is now responsible for implementation of the National Institute for Health Research (NIHR). She also chairs the UK Clinical Research Collaboration (UKCRC) and is a member of the Board of the Office of Coordination of Health Research (OSCHR) and of the Medical Research Council. She was a member of the steering group for the Biotechnology Innovation and Growth Team, chaired by Sir David Cooksey and its "Refresh", the Health Care Industry Task Force and is a member of the UK Health Innovation Council. She is a member of the WHO Global Advisory Committee on Health Research (ACHR) and chaired the Expert Advisory Committee for the development of the WHO research strategy, submitted as a resolution to the World Health Assembly 2009. She is a member of the International Advisory Committee for A*STAR, Singapore and the Caribbean Health Research Council and advises many others on research strategy and evaluation including the Australian NHMRC.

Professor David Denning is Professor of Medicine and Medical Mycology and Director of the National Aspergillosis Centre, Manchester. Professor Denning's research interests include the diagnosis and treatment of invasive aspergillosis, other life-threatening fungal infections, respiratory fungal allergy, antifungal resistance, the assessment of new antifungal agents and the genomics of the *Aspergilli*. He is a Founder of the antifungal discovery and development company F2G Ltd and the molecular diagnostic company Myconostica Ltd.

Dr Sujal R Desai is a Consultant Radiologist at King's College Hospital Foundation NHS Trust. Dr Desai trained in medicine at the Middlesex Hospital Medical School (University of London) and in radiology initially at King's College Hospital and later at the Royal Brompton Hospital, where he was awarded an MD for his thesis in structural-functional relationships in fibrotic lung diseases. Dr Desai is a fellow of the Royal College of Physicians and the Royal College of Radiologists.

Dr Desai is the radiology lead for imaging of pulmonary diseases and haematological malignancies. Together with Dr Roopen Arya, he was instrumental in establishing the King's College Hospital protocol for investigation of patients with suspected acute embolism and continues as the lead for imaging acute and chronic thromboembolic disease. In addition to his research interest in diffuse interstitial lung diseases, Dr Desai has an interest in pulmonary vascular disease, in general, and specifically, in patients with sickle cell disease.

Dr Kev Dhaliwal is Clinical Lecturer in Respiratory Medicine and MRC Clinical Training Fellow at the MRC Centre for Inflammation Research, Queens Medical Research Institute at the University of Edinburgh. His research interests are in: functional molecular imaging of inflammation, in particular optical imaging; applying imaging to delineate the role of monocytes in acute lung injury; pneumonia; and the fibroproliferative response.

Professor Roland M du Bois is Professor of Medicine in the Department of Medicine at the National Jewish Health, Denver, Colorado and Senior Research Investigator, Department of Population Genetics and Gene Therapy at the National Heart and Lung Institute, Imperial College, London. His current research interests include the genetic predisposition to interstitial lung diseases in the Divisions of Pulmonary Medicine and Occupational and Environmental Health Sciences at National Jewish and studies of novel therapies for interstitial lung disease.

Professor Stuart Elborn is Professor of Respiratory Medicine and Deputy Director of the Centre for Infection and Immunity at Queens' University and Director of the Adult CF Centre in Belfast City Hospital. His main research interests are in infection in the CF lung, developing models of infection and inflammation and clinical trials. He is current Chair of the Research Advisory Committee of the CF Trust and President of the European CF Society.

Professor Timothy Evans is Head of the Unit of Critical Care Medicine, Imperial College School of Medicine; and Professor of Intensive Care Medicine and Consultant Thoracic Physician at Royal Brompton and Harefield NHS Foundation Trust. His research interests include the vascular biology of sepsis and the pathophysiology of acute respiratory distress syndrome.

Professor Adam Finn is Professor of Paediatrics and Head of the Academic Unit of Child Health at the University of Bristol and Honorary Consultant in Paediatric Infectious Diseases and Immunology at Bristol Royal Hospital for Children. His main research interests include mucosal immunology of bacterial vaccines and clinical trials in children.

Professor Andrew Fisher graduated from Nottingham University in 1993. He received research training as an MRC training fellow in Newcastle and Edinburgh between 1996 and 1999 and graduated PhD in Lung Transplantation in 2001 from Newcastle University. He completed specialist training in Respiratory Medicine in the Northern Deanery in 2003 and was subsequently awarded a GlaxoSmithKline Senior Clinical Fellowship in 2004. He has worked in the Institute of Cellular Medicine as a Senior Lecturer and Honorary Consultant Respiratory and Transplant Physician at Freeman Hospital, Newcastle upon Tyne. He was appointed Professor of Respiratory Transplant Medicine at Newcastle University in 2009.

SPEAKERS' BIOGRAPHICAL DETAILS

Dr David Fishwick is a Reader in Respiratory Medicine in the Department of Respiratory Medicine at the University of Sheffield and Honorary Consultant Respiratory Physician at the Royal Hallamshire Hospital and the Co-Director of the Centre for Workplace Health. He has a clinical and research interest in all aspects of occupational lung diseases.

Dr R Andres Floto is a Wellcome Trust Senior Fellow based in the Cambridge Institute for Medical Research, University of Cambridge, where his research focuses on understanding the regulation of antigen processing by macrophages and dendritic cells during infection (particularly with mycobacteria) and how it can be manipulated therapeutically. As an Honorary Consultant at Papworth Hospital, Cambridge, his clinical interests centre on cystic fibrosis (CF), non-CF bronchiectasis and non-tuberculous mycobacterial infections.

Dr Judith Garcia-Aymerich is a Respiratory Epidemiologist at the Centre for Research in Environmental Epidemiology (CREAL) in Barcelona. She completed her Medicine Degree in 1996 and Doctor in Public Health and Methodology of the Biomedical Research in 2002. She is currently focused on the study of phenotypic heterogeneity of COPD, and leads the research area about physical activity and chronic respiratory diseases (asthma and COPD).

Dr Mark Griffiths is Consultant Physician in the Adult Intensive Care Unit at the Royal Brompton Hospital and Honorary Reader in Critical Care at Imperial College London. He is Acute Respiratory Failure Consortium Lead for the NIHR Biomedical Research Unit in Advanced Lung Diseases, RBHT. Dr Griffiths' clinical and research interests are: acute lung injury, alveolar epithelial cell responses to injury and mechanical stimulation and biomarkers of parenchymal lung diseases. He is a founder member of the UK and Ireland acute lung injury research group UKELELE.

Professor Jonathan Grigg is the Professor of Paediatric Respiratory and Environmental Medicine at Barts and the London School of Medicine and Dentistry. He qualified in 1982 from the London Hospital, and trained in paediatrics at Great Ormond Street and Oxford. After a three year clinical research fellowship at the Royal Postgraduate Medical School, and a research fellowship in the Department of Paediatric Leukocyte Biology at the Texas Children's Hospital, he became a Clinical Research Fellow in the Department of Thoracic Medicine at the Royal Children's Hospital Melbourne. On return to the UK in 1996, he was appointed as a Senior Lecturer in Paediatric Respiratory Medicine at the University of Leicester, and then moved to the London Hospital in 2006. Professor Grigg's current research interests include: the effect of air pollution on pulmonary innate immunity; treatment of preschool wheeze; and the management of difficult asthma in school age children.

Dr Mike Grocott is a Consultant in Critical Care Medicine at Southampton University Hospitals NHS Trust and Senior Lecturer in Critical Care at the UCL Institute of Child Health. He is the Director of the UCL Centre for Altitude Space and Extreme Environment Medicine and led the Caudwell Xtreme Everest expedition in the spring of 2007.

Dr David R Harper is Chief Scientific Officer at Biocontrol Limited, Nottingham. Biocontrol holds the leading position in developing bacteriophage-based therapeutics. Initial work is targeting *Pseudomonas aeruginosa* infections of the ear, skin and lung. Phase 2 trials have been completed for topical infections, and an aerosolised therapeutic has been developed and is expected to enter clinical trials during 2010.

Dr Kim Harrison was born in Preston, Lancashire and went to Hutton Grammar School. He studied medical sciences at Selwyn College, Cambridge and clinical medicine at University College Hospital, London. He became fascinated by respiratory disease whilst working as a junior doctor in the East End of London during the early 1980s. After gaining experience in General Internal Medicine, Kim obtained a post as Registrar at the Brompton Hospital. It was here, working for Professor Margaret Turner-Warwick, that he developed an interest in interstitial lung disease. He was subsequently made Honorary Lecturer at the National Heart and Lung Institute where he wrote his MD thesis on 'Pulmonary collagen metabolism in systemic sclerosis' under the supervision of Professor Geoff Laurent. Dr Harrison left London in 1994 to become Consultant Chest Physician at Morriston Hospital, Swansea where he has developed the Respiratory Unit's reputation for clinical excellence, teaching and research. He is currently Senior Clinical Lecturer in the Medical School at Swansea University and has research interests in the pathogenesis of pulmonary fibrosis the aetiology of cough in idiopathic pulmonary fibrosis. He sits on the BTS Science and Research Committee and has been Chairman of the British Association for Lung Research since 2005.

Professor Christopher Haslett OBE is Director of the Queen's Medical Research Institute, Professor of Respiratory Medicine and Director of the Rayne Laboratories at the University of Edinburgh. In addition, he is also an active clinician in his capacity as Honorary Consultant Physician at the Royal Infirmary of Edinburgh. Professor Haslett's key research interests are: mechanisms of the resolution of inflammation; granulocyte apoptosis and imaging the inflammatory response. Professor Haslett is spearheading Edinburgh's major research initiative into the impact of imaging technologies in clinical research.

Dr Nik Hirani is a Senior Clinical Lecturer at Edinburgh Royal Infirmary and PI in the University of Edinburgh MRC Centre for Inflammation Research. He runs a specialist lung fibrosis clinic, chairs the BTS interstitial lung disease specialist advisory group and co-chaired the BTS ILD guideline committee. He has a research interest in oxygen-regulated mechanisms in lung injury and fibrosis.

Professor Stephen Holgate. Applying basic science to the clinical interface in asthma and allied disorders has been the guiding principle of Stephen Holgate's career. After qualifying in Medicine at Charing Cross Hospital Medical School, London and spending two years at Harvard, he has pursued an academic career leading to his appointment in 1987 to his current position as Medical Research Council Clinical Professor of Immunopharmacology at the University of Southampton, UK. His research interests have been largely focused on the cellular and molecular mechanisms of asthma that has involved use of both epidemiological and genetic approaches. He has published over 870 papers in the peer

SPEAKERS' BIOGRAPHICAL DETAILS

reviewed literature, 50 books and 300 reviews and book chapters and until 2009 was co-editor of Clinical and Experimental Allergy for 25 years. He is currently Chairman of the Science Council's Science in Health Group, was a member of the Royal Commission on Environmental Pollution and Chairman of the MRC Population and Systems Medicine Board and member of MRC Strategy, as well as being involved in advising Government on issues relating to air pollution and nanomaterials. He has established an MRC Oversight Group on CFS/ME to explore new ways of stimulating research in this field.

Dr Nicholas Hopkinson is a Clinical Senior Lecturer at The National Heart and Lung Institute of Imperial College and the Royal Brompton and Chelsea and Westminster Hospitals. His research interests are in pulmonary physiology, skeletal muscle impairment and exercise limitation in COPD and other respiratory conditions. His work has been funded by the MRC, the British Lung Foundation and The Wellcome Trust.

Dr John Hurst is a Clinical Senior Lecturer at UCL Medical School, and an Honorary Consultant in Respiratory and Acute Medicine at Royal Free Hampstead NHS Trust, London. His clinical and research interest is COPD, particularly the utility of biomarkers at exacerbation and in the assessment of co-morbidities.

Dr Richard Iles is a Consultant in Respiratory Paediatrics at Addenbrooke's NHS Trust in Cambridge. He qualified from the University of London (St Thomas's) in 1985, and was trained at RHSC Edinburgh, HSC Toronto and Alder Hey Children's Hospital in Liverpool. He was appointed at Addenbrooke's in 1997. He has been director of The Paediatric Cystic Fibrosis Network for Norfolk, Suffolk and Cambridgeshire since its inception in 2003. He is an Honorary Senior Lecturer in Health Economics at the University of East Anglia, Norwich. Dr Iles' clinical interests are paediatric cystic fibrosis and chronic lung disease of prematurity. His research interests are health economics and non invasive pulmonary function monitoring.

Dr Gisli Jenkins is Senior Lecturer at the University of Nottingham, having trained in respiratory medicine in London. He completed his PhD at University College London and his post-doctoral studies at University of California at San Francisco. His research has focused on the pathobiology of pulmonary fibrosis and airway remodelling, and is funded through grants from the ARC, Asthma UK, MRC and the Wellcome Trust.

Professor Sebastian Johnston is Professor of Respiratory Medicine and Allergy at the National Heart and Lung Institute, and Honorary Consultant Physician in Respiratory Medicine and Allergy at St Mary's Hospital, London. He is Principal Investigator in the MRC and Asthma UK Centre in Allergic Mechanisms of Asthma and the Centre for Respiratory Infection, and Respiratory Team Leader for the NIHR funded Biomedical Research Centre.

Dr Hazel Jones is a Research Fellow at Imperial College with more than 20 years experience in the use of PET in the lung. She employs *in vitro* techniques and animal models to validate and interpret PET data acquired using markers targeted at components of pulmonary inflammation and applies these techniques in human lung disease.

Dr Ian Ketchell currently holds the position of Director of the Adult Cystic Fibrosis Centre and Consultant Physician in Respiratory and General Medicine at University Hospital Llandough and Honorary Lecturer, Cardiff University. Research interests include cystic fibrosis, asthma, airway inflammation and clinical trials.

Professor Peter Le Souëf is currently Professor of Paediatrics and Head of the School of Paediatrics and Child Health at the University of Western Australia and a Paediatric Respiratory Physician. He trained in London, Toronto and Melbourne. Professor Le Souëf's research interests include infant respiratory physiology, paediatric aerosol medicine, asthma epidemiology and molecular genetics and immunogenetics. Current research focuses on mechanisms of acute asthma in children and geoclimatic factors influencing the evolution of human immune responses.

Professor Y C Gary Lee is a Winthrop Professor of Respiratory Medicine and Consultant Chest Physician at the University of Western Australia. He leads a clinical and a laboratory research group at the Lung Institute of Western Australia, focusing on translational pleural research. He is the editor of *Respirology* and the International Pleural Newsletter, and a panel member for the BTS pleural disease guidelines 2009.

Dr Marc Lipman is a Senior Lecturer and Consultant in Respiratory and HIV Medicine at the Royal Free Hospital, London. He is chair of the BTS TB specialist advisory group and a member of the HPA TB Programme Board. His research interests focus on tuberculosis, respiratory infection and HIV.

Dr Stephen Loring is Scientific Director of Respiratory Therapy at Beth Israel Deaconess Medical Center and Associate Professor of Anesthesiology at Harvard Medical School. He teaches respiratory pathophysiology, conducts basic research on mechanisms of mesothelial lubrication and pleural space physiology, and applies respiratory physiology to studies in human volunteers and patients.

Dr Toby Maher is a Consultant Respiratory Physician at the Royal Brompton Hospital. Prior to this he was a Wellcome Trust Clinical Research Fellow at the Centre for Respiratory Research, UCL. His research interests include biomarker discovery and studying the role of prostanooids and apoptosis in the pathogenesis of IPF.

Professor John Maina is a veterinarian by profession, with a BVM from the University of Nairobi and PhD and DVSc from the University of Liverpool. His research has been in the field of functional comparative respiratory morphology. He studies the design of gas exchangers in animals that live in diverse habitats, operate at different metabolic levels, lead various lifestyles and utilise different respiratory fluid media.

Dr Patrick Mallia is a Walport Clinical Lecturer at the National Heart and Lung Institute at Imperial College Healthcare Trust, London, UK. His research interests are the role of respiratory viruses in exacerbations of COPD and asthma.

Dr William Man is Consultant Chest Physician and National Institute for Health Research Clinician Scientist at the Royal

Brompton and Harefield NHS Foundation Trust. His research interests include pulmonary rehabilitation and skeletal muscle dysfunction in COPD.

Professor Sir Alexander Markham completed a Chemistry PhD at the University of Birmingham in 1974 and has undertaken postdoctoral work in Japan, London, Cambridge (UK) and Boston (USA). He entered the commercial sector and had some 15 years' experience in the pharmaceutical and diagnostics industries in both the UK and the USA, with GD Searle and then ICI Pharmaceuticals (now Astra Zeneca). His commercial experience includes both drug development (Gefitinib) and the worldwide introduction of DNA Fingerprinting for forensic and medico-legal applications. This was recognised by the Queen's Award for Technological Achievement in 1990.

He qualified clinically in 1985, training at London and Oxford, and is accredited in pathology and internal medicine. He is the Professor of Medicine in the University of Leeds and directed the Molecular Medicine Institute at St James's University Hospital. He has undertaken a range of administrative duties at national and international level, including the chairmanship/membership of numerous committees for the Medical Research Council, the Department of Health and the Wellcome Trust, and the International Agency for Research on Cancer (IARC), the Deutsche Krebshilfe, the Singapore Government Agency for Science Technology and Research (A-STAR), the Li Ka Shing Institute of the Chinese University of Hong Kong and the American Association for Cancer Research.

A Fellow of the Academy of Medical Sciences and a Board Director of the International Union against Cancer (UICC), he was, until recently, chairman of the National Cancer Research Institute (NCRI). He has been a founder member of the UK Clinical Research Collaboration (UKCRC) Board and the National Institute of Health Research Advisory Board. He remains a member of the Government's Cancer Reform Strategy (2007) Advisory Board, and chaired its Clinical Outcomes Group.

Professor Markham was Chief Executive of Cancer Research UK for four years. He then returned to academic work at Leeds University but continues as Senior Medical Advisor to CR-UK. He serves on the Department of Health Ministerial/Industry Strategy Group and is Chairman of the Office for Strategic Coordination of Health Research (OSCHR), Translational Medicine Board. He is also the Department of Health Senior Responsible Owner and Board Chairman of the 'Research Capability Programme' in NHS "Connecting for Health" and Chairman of the Arthritis Research Campaign Scientific Strategy Committee. He was knighted for 'Services to Medicine and to Healthcare' in the Queen's 2008 New Year Honours List.

Dr Daniel McAuley works as a Senior Lecturer/Consultant in Intensive Care Medicine at the Royal Victoria Hospital, Belfast. His major research area is acute lung injury. He is Vice Chair of the Irish Critical Care Trials Group, Co-Director of research for the Intensive Care Society and a founder member of the UK and Ireland Acute Lung Injury research group.

Dr Helen McShane qualified in medicine in 1991 and after junior hospital jobs, she was awarded an MRC Clinical Training Fellowship in 1997. She undertook a PhD with Professor Adrian Hill in Oxford to work on new TB vaccines. In 2001, she was

SPEAKERS' BIOGRAPHICAL DETAILS

awarded a Wellcome Trust Clinician Scientist Fellowship, to evaluate these vaccines in clinical trials. In 2003, she became a Consultant in HIV and GU medicine, and in June 2005 was awarded a Wellcome Trust Senior Clinical Fellowship. She now leads the TB vaccine programme at Oxford University. In July 2008, she was appointed FRCP, and in September 2008 was appointed a Reader in Vaccinology by the University of Oxford.

Dr Ross Metzger is a UCSF Fellow in the Department of Anatomy at the University of California, San Francisco. Before starting his laboratory at UCSF, he trained with Mark Krasnow at Stanford University.

Professor Ann Millar is Professor of Respiratory Medicine at the University of Bristol, having trained in London and Liverpool. She has clinical interests in diffuse parenchymal lung disease, acute lung injury and the immunocompromised lung. Professor Millar's research interests are in the mechanism regulating the outcome of acute and chronic lung injury.

Professor Tim Mitchell did his first degree in Biological Sciences at the University of Birmingham, UK. He remained at the University of Birmingham to complete a PhD studying the modes of action of toxin A from *Clostridium difficile*. A Wellcome Trust travelling fellowship then funded a two year post-doctoral position at Erasmus University, Rotterdam, The Netherlands to study eukaryotic cell signalling in response to bacterial toxins. A return to the UK in 1987 saw his first encounter with *Streptococcus pneumoniae* while working in the laboratory of Graham Boulnois at University of Leicester, UK. Professor Mitchell was awarded a Royal Society University Research Fellowship in 1992 and was appointed to the Chair of Microbiology at the University of Glasgow in 1997. The underlying theme of Professor Mitchell's work is understanding the molecular pathogenesis of infections caused by *Streptococcus pneumoniae* and using this information to design new treatment or vaccine strategies for these diseases.

Professor Denis Mitchison has continued his life-long work on the development of the modern treatment of tuberculosis at St George's, University of London, as an Emeritus Professor. With the aim of shortening the current 6-month treatment period, he has organised clinical trials of rifapentine, and the fluoroquinolones, and has developed quantitative bacteriological assessments of drug action.

Professor Miriam F Moffatt is Professor in Respiratory Genetics based at the National Heart and Lung Institute at Imperial College. Along with Professor Bill Cookson, she heads the Molecular Genetics Group. Together they have been investigating the genetic mechanisms underlying asthma for the past 20 years using candidate gene and positional cloning approaches and most recently genome wide association studies.

Professor Nick Morrell is the British Heart Foundation Professor of Cardiopulmonary Medicine at the University of Cambridge School of Clinical Medicine, Addenbrooke's and Papworth Hospitals. His major research interest is in the molecular basis of pulmonary arterial hypertension and the translation of these studies into novel therapies. He is the Research Director of the Pulmonary Vascular Diseases Unit at Papworth Hospital.

SPEAKERS' BIOGRAPHICAL DETAILS

Professor John Moxham studied economics at the London School of Economics 1964–67 and was subsequently a Research Fellow at LSE. He undertook his medical training at University College Hospital, qualifying in 1973. His clinical training in general and respiratory medicine included positions at University College Hospital, Hammersmith Hospital, and Brompton Hospital. From 1977–1980 he was a Lecturer in Medicine at University College Hospital researching respiratory muscle physiology. In 1982 he was appointed as a Consultant Physician to King's College Hospital and in 1990 was appointed Professor of Respiratory Medicine. For 30 years his research interests have been respiratory physiology, including respiratory muscle weakness, neural respiratory drive, breathlessness, ventilatory failure, non-invasive intervention, and pulmonary rehabilitation. He has supervised more than 40 research students and currently his research group's interests include breathlessness, cough function in stroke, and skeletal muscle function in chronic lung disease.

In 1997 he became Dean of the Faculty of Clinical Medicine, in 1998 Dean of the King's College Hospital campus, and in 2000 Vice Dean of King's College London School of Medicine. In 2003 he relinquished his medical school administrative posts to become Medical Director at King's College Hospital.

Dr Martin Muers was a Consultant Respiratory Physician and General Physician at the Leeds Teaching Hospitals NHS Trust from 1980 to 2008, where he was also a Senior Clinical Lecturer at the University of Leeds. His major clinical and research interests have been lung cancer, mesothelioma and chronic obstructive pulmonary disease. He has been a member of several national and international guideline groups. He has published papers on mesothelioma, and symptom control and quality of life in lung cancer patients.

Professor Robert Naeije is Professor of Physiology and Medicine and Chairman of the Department of Pathophysiology at the Faculty of Medicine of the Free University of Brussels. He is also Consultant at the Pulmonary Hypertension Clinic of Department of Cardiology of the Erasme University Hospital, Brussels. Professor Naeije has a long publication record of fundamental and clinical research on the pulmonary circulation. He has served on scientific advisory boards of several randomized controlled trials of new specific pharmacologic treatments of pulmonary arterial hypertension. He was actively involved in the Evian (1998), Venice (2003) and Dana Point (2008) world expert consensus conferences on pulmonary hypertension. Professor Naeije's current research interests include various pathophysiological and therapeutic aspects of pulmonary arterial hypertension, and the pathobiology of experimental animal models of congenital cardiac shunt-associated pulmonary hypertension. On the clinical side, his team has developed original methods for an improved non invasive evaluation of the pulmonary circulation and right ventricular function, with recent focus on tissue Doppler imaging techniques and exercise stress testing. Professor Naeije has directed several high altitude medical expeditions. He has been a member of the editorial board of the American Journal of Respiratory and Critical Care Medicine and is currently Associate Editor of the European Respiratory Journal. He serves on the Pulmonary Circulation group and Congress Planning Committee of the American Thoracic Society.

Professor Sir Anthony Newman Taylor is Deputy Principal of the Faculty of Medicine at Imperial College. Since 1977 he has been a Consultant Physician at the Royal Brompton Hospital, where for several years he was Deputy Chief Executive, Medical Director and Director of Research. From 2006 to 2008 he was Head of the National Heart and Lung Institute. He was a member of the Industrial Injuries Advisory Council, an expert advisory group to the Department for Work and Pensions, between 1982 and 1986 and Chairman between 1996 and 2008. He is currently Chairman of the Colt Foundation.

Professor Kenneth O'Byrne is a Consultant Medical Oncologist with a particular interest in the management of thoracic malignancies. He is Clinical Director of the HOPE Directorate at St James's Hospital and Clinical Professor at Trinity College, Dublin. Professor O'Byrne qualified from University College, Dublin in 1984, completed his higher professional training in oncology at the Churchill Hospital, Oxford in 1997 and subsequently worked as a Consultant and Senior Lecturer in Medical Oncology at the University Hospitals of Leicester NHS Trust and University of Leicester until October 2003, before returning to Dublin in November 2003. He has a Doctorate Degree in Medicine from UCD obtained in 1998 and is a Fellow of the Royal College of Physicians, Ireland. Professor O'Byrne is a founder member and President of the British Thoracic Oncology Group (BTOG) and British Mesothelioma Interest Group and sits on the UK National Cancer Research Institute Lung Clinical Studies Group committee. He chairs the International Association for the Study of Lung Cancer Fellowship Committee. Professor O'Byrne is an active member of the Irish Society of Medical Oncology, Irish Clinical Oncology Research Group, All Ireland Lung Cancer Forum, European Organisation for the Research and Treatment of Cancer Lung Cancer Group, British Association for Cancer Research, American Society of Clinical Oncology and the American Association for Cancer Research. Since returning to Dublin, Professor O'Byrne has set up the Thoracic Oncology Research Group based within the Clinical Trials Unit and the Institute of Molecular Medicine on the St James's Hospital Campus. The group has an interest in carcinogenesis, identification of novel biomarkers and novel targeted therapy in lung cancer and mesothelioma. He has edited two text books in thoracic oncology and published over 150 manuscripts in peer-reviewed books and journals.

Professor Peter Openshaw is the Director of the Centre for Respiratory Infection and Professor of Experimental Medicine at the National Heart and Lung Institute, Imperial College London. His interests are pandemic influenza, immune protection against RSV disease, vaccines and the relationship of viral infections to wheezing disorders. His current research is on the immunopathogenesis of viral disease, specifically on innate defences, vaccines, neonatal immunology and regulatory T cells.

Professor Peter Ormerod. Tuberculosis at the age of seven made Professor Ormerod decide to be a doctor. After qualification in Manchester in 1974, he trained in general and respiratory medicine in Manchester and Birmingham. He was appointed Consultant Chest Physician in Blackburn, a high TB incidence area in 1981, where he runs the TB Service, and continues to be a full-time I2.0PA clinician. He was awarded an MD in 1986 and a DSc(Med) in 2000 for tuberculosis research

by Manchester University, and the Weber-Parkes Prize by the RCP London in 2002. He has been a member of the Joint TB Committee of the British Thoracic Society since 1987 (Chairman 1995–2000). Professor Ormerod has published over 90 papers on clinical and epidemiological aspects of TB, plus 14 book chapters and a book on Clinical TB cases. He sits on a number of Government Advisory bodies on aspects of tuberculosis. He is the current President of the British Thoracic Society.

Professor Martyn R Partridge is Professor of Respiratory Medicine in Imperial College London, National Heart and Lung Institute Division, based at the Charing Cross Hospital, and Honorary Consultant Physician to Imperial College Healthcare NHS Trust. He is Lead Director of the North West London Comprehensive Local Research Network. His academic interests are in evaluating the delivery of respiratory health care including patient centred approaches and E learning. Professor Partridge is Immediate Past President of the British Thoracic Society. For two decades he was (Honorary) Chief Medical Advisor to Asthma UK and was involved in the production and dissemination of the British Asthma Guidelines from 1989 to 2008. He currently chairs the UK Department of Health Asthma Steering Group and serves on the prevention of non communicable lung disease working party of the WHO. He was an elected member of the Council of the Royal College of Physicians from 2006–2008, and is Final Year Undergraduate Coordinator for the Faculty of Medicine, Imperial College London and on the Clinical Steering Committee of London Ambulance Service.

Professor Andrew Peacock is the Director of the Scottish Pulmonary Vascular Unit, which looks after all the patients with pulmonary hypertension in Scotland (population 5 million). He is also Professor in Medicine at the University of Glasgow (Respiratory Medicine). Professor Peacock trained at St Bartholomew's Hospital Medical College, London, Caius College Cambridge, Brompton Hospital, London, UK and at the University of Colorado Health Sciences Centre, USA, where he studied the effect of high altitude on the pulmonary circulation of chickens! Hypoxia remains the main theme of his research because it combines the science of the pulmonary circulation with an unhealthy interest in mountains. His laboratory studies the effects of hypoxia on pulmonary vascular-cell proliferation and on the physiological responses of the human pulmonary circulation. He has been involved in many of the clinical trials of new therapies for pulmonary hypertension in the last years, and has spent time developing new end points in the assessment of patients with pulmonary vascular disease. Professor Peacock is Secretary of the Pulmonary Circulation Group of the European Respiratory Society and the author of more than 150 papers, reviews and chapters on pulmonary vascular disease. He is co-editor with Lew Rubin of *Pulmonary Circulation* (2nd Edition): diseases and their treatments (3rd Edition in process).

Professor Michael Polkey is Consultant Physician in the Department of Sleep and Ventilation at the Royal Brompton Hospital and Professor of Respiratory Medicine at the National Heart and Lung Institute, London. His research interests include mechanisms of respiratory failure, systemic aspects of COPD and lung volume reduction surgery.

SPEAKERS' BIOGRAPHICAL DETAILS

Professor Neil B Pride is an Emeritus Professor and senior research investigator at the National Heart and Lung Institute, Imperial College. Before retirement he was Professor of Respiratory Medicine at the Royal Postgraduate Medical School at Hammersmith Hospital. His main research interests have been in applied respiratory physiology, particularly respiratory mechanics, and in various aspects of COPD and other diseases of the airways.

Dr Helen C Rodgers is a Consultant Respiratory Physician at the Western General Hospital, Edinburgh and Honorary Senior Clinical Lecturer at the University of Edinburgh. She has a special interest in cystic fibrosis and has worked in this area for the last 14 years. Dr Rodgers is Director of the Scottish Adult CF service and leads the CF outreach service in Dundee. She qualified from Leeds University in 1990 and trained in respiratory medicine in Nottingham. Her interest in CF began in 1995 when working as the CF Fellow in Edinburgh. She went on to become CF Trust Fellow in Nottingham from 1996 to 2000, where she completed a Doctor of Medicine researching ion transport and inflammation in Cystic Fibrosis. She has been a consultant in Edinburgh for six years.

Dr Robin Rudd, formerly Consultant Physician at St Bartholomew's and the London Chest Hospitals, continues his research interests in thoracic oncology and asbestos related disease as co-chair of the London Lung Cancer Group and co-director of Barts Mesothelioma Research, as well as clinical and medico-legal work in private practice.

Professor Tariq Sethi is Professor of Respiratory and Lung Cancer Biology at the University of Edinburgh. His research is focused on the role of inflammation in the regulation of lung cancer proliferation and drug resistance.

Dr Alan Smyth is an Associate Professor and Reader in Child Health at the University of Nottingham and Honorary Consultant in Paediatric Respiratory Medicine at Nottingham University Hospitals NHS Trust. He has worked at the NUH for 13 years and has established the paediatric bronchoscopy service and the diagnostic service for sleep disordered breathing there. He is Director of the Nottingham Children and Young Person's Cystic Fibrosis Clinic, which provides care for 160 children. He also sees children with asthma, TB, HIV, specialist respiratory problems and general paediatric problems. Dr Smyth is a member of the Nottingham Respiratory Biomedical Research Unit. He has a major research interest in novel ways of treating infection in cystic fibrosis and his group has published the results of the TOPIC trial – a multi-centre trial of once versus three times daily dosing with tobramycin. The group also has ongoing projects looking at inhibition of bacterial communication. By way of contrast they are also looking at more effective ways of communicating with children with asthma. From 2006 Dr Smyth has taken on the post of Director of the Trent Local Research Network, under the Medicines for Children Programme. When not working, he loves cycling, runs half marathons (increasingly slowly) and tries to keep up with his children.

Professor Rosalind L Smyth is Brough Professor of Paediatric Medicine and Head of the Division of Child Health at the University of Liverpool. She chairs the Commission on Human

SPEAKERS' BIOGRAPHICAL DETAILS

Medicine's Paediatric Expert Advisory Group and is Director of the NIHR Medicines for Children Research Network.

Dr David Spencer is a Consultant in Respiratory Paediatrics in Newcastle. He trained in paediatrics in Edinburgh, London and the West Midlands before moving to Newcastle in 1996. His clinical and research interests include the consequences of community acquired pneumonia in children, non-CF bronchiectasis and the epidemiology of empyema in children.

Dr Michael Steiner is a Consultant Respiratory Physician at Glenfield Hospital, University Hospitals of Leicester NHS Trust. His clinical and research interests are in the field of rehabilitation and chronic care in COPD. Dr Steiner has a particular expertise in exercise performance, rehabilitation, nutrition and skeletal muscle dysfunction in COPD and other long term conditions.

Dr Daniel Sterman received his AB in European History from Brown University in 1985, and his MD from Cornell University Medical College in 1989. He is currently Associate Professor of Medicine and Associate Professor of Medicine in Surgery, and the Director of the PENN Interventional Pulmonology Programme and Clinical Director of the Thoracic Oncology Gene Therapy Programme of the Centre for Lung Cancer and Related Disorders of the University of Pennsylvania Medical Center. Dr Sterman has advanced training in the following techniques: flexible and rigid bronchoscopy; balloon bronchoplasty, endobronchial stent placement, endobronchial brachytherapy, photodynamic therapy, auto-fluorescence bronchoscopy (LIFE), transbronchial needle aspiration/biopsy, bronchoscopic electrocautery, endobronchial ultrasound, percutaneous tracheotomy and pleuroscopy. Dr Sterman's clinical interests are related to the treatment of thoracic malignancies, specifically as they apply to the synergy of molecular medicine and novel technologies in interventional pulmonology. His research interests are in the translation of laboratory discoveries from the bench to the bedside: conducting human clinical trials of gene therapy and vaccine therapy for lung cancer, mesothelioma, and other pleural malignancies. He has also been involved in pioneering clinical research projects aimed at developing advanced bronchoscopic techniques to treat diseases such as severe asthma, emphysema and prolonged post-operative air leaks.

Professor Terry Tetley Heads the Section of Pharmacology and Toxicology within the Division of the National Heart and Lung Institute, Imperial College. She is also Professor of Lung Cell Biology and Senior Tutor in the Faculty of Medicine. Professor Tetley's research focuses on mechanisms of pulmonary inflammation due to cigarette smoke, particulate air pollution, engineered nanoparticles and infection. She has established novel in vitro models to investigate primary human alveolar epithelial cell, macrophage and dendritic cell interactions in response to toxicants.

Dr David Thickett is a Wellcome Intermediate Fellow and Senior Lecturer in Clinical and Experimental Medicine at the

University of Birmingham. He is an Honorary Consultant in Respiratory Medicine at University Hospital NHS Trust and an Honorary Consultant at the Heart of England NHS Trust. His research interests are in basic lung biology (VEGF and type II cells) as well as translational clinical studies in acute lung injury and interstitial lung disease.

Dr John P Watson is a Consultant in Respiratory Medicine in the Leeds Teaching Hospitals NHS Trust, where he also leads the Leeds Tuberculosis Clinic. He is a member of the British Thoracic Society and of its advisory group for tuberculosis, and is a member of the National MDR TB Advisory Service. He is interested in all clinical aspects of tuberculosis including TB screening.

Professor Wisia Wedzicha is Professor of Respiratory Medicine at UCL Medical School, University College London. She qualified from Somerville College, Oxford University and St Bartholomew's Hospital Medical College, London University. She has a major interest in the causes, mechanisms and impact of COPD exacerbations; she runs an active research group on this topic and has published extensively on issues relating to COPD exacerbations. She also is an expert on home oxygen therapy and non invasive ventilation in COPD. Professor Wedzicha has chaired the British Thoracic Society (BTS) working group on home oxygen therapy and is a member of the Guideline Development Group for the revision of the NICE COPD guidelines. She chaired the Acute and the Medicines, Devices and Intervention sub-groups for the Department of Health COPD Clinical Strategy and is a member of the Clinical Strategy Programme Board. She is Editor in Chief of *Thorax*, a member of the editorial board of *BioMed Central (Medicine)*, a member of the BMJ advisory board and on the editorial board of *AJRCCM*.

Dr Jim M Wild is a Reader in Magnetic Resonance Physics and Project Leader: Hyperpolarised Gas MRI in the Academic Unit of Radiology at the University of Sheffield. His primary research area is hyperpolarised gas MRI physics: technical implementation of novel MR methods to image inhaled hyperpolarised gases in the lungs. His research is focused on pulse sequence development for lung imaging, NMR physics of gases in the lungs and design of dedicated imaging and polarisation hardware for ^3He and ^{129}Xe MRI. He is also interested in clinical applications in PH, COPD, asthma, lung cancer and CF.

Dr Sylvia Worthy is a Consultant Thoracic Radiologist at the Newcastle upon Tyne Hospitals. She learned the art of thoracic radiology with Professor Nestor Muller in Vancouver, Canada and brought the expertise back to Newcastle, to develop and lead the thoracic radiology service at Newcastle upon Tyne Hospitals since 1997. A particular interest has been training the thoracic radiologists of the future; medical education, being Programme Director for Radiology for the Northern region since 2003, and more recently Head of the School for Radiology; and revealing the mysteries of radiology to respiratory physicians, through developing the BTS Chest Radiology Course in Newcastle and teaching on the Oxford BTS Chest Radiology Course.

EXHIBITORS' INFORMATION

Actelion Pharmaceuticals UK Ltd **Stand number 10**

Actelion Pharmaceuticals UK Ltd is an affiliate of Actelion Pharmaceuticals Ltd, with its UK headquarters based in London, focusing on the commercialisation of innovative treatments to serve high unmet medical needs. Please come and visit stand 10 for more information on pulmonary arterial hypertension.

Tel: +44 (0) 20 8987 3336

Email: rachel.fortes@actelion.com

Website: www.actelion.com

Aerocrine **Stand number 2**

Aerocrine is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. The pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable the fast and reliable measurement of airway inflammation and may thus play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma.

Tel: +44 (0) 1753 884266 or +44 (0) 7760 267420

Email: sales.uk@aerocrine.com

Website: www.aerocrine.com

Air Products **Stand number 39**

Air Products is a global provider of home respiratory services. We serve 420,000 patients across the world through the provision of respiratory therapies, such as CPAP, oxygen, NIV, nebuliser and infusion services in their homes. In the UK, we provide the NHS Home Oxygen Service to over 50,000 patients across England and Wales. Our specialist teams serve patients with conditions ranging from chronic lung disease, asthma and emphysema to sleep apnoea. And we strive to improve their quality of life, by supporting clinicians through the provision of therapy equipment to patients in the home environment, offering 24/7 technical support and sharing therapy compliance data.

Tel: +44 (0) 845 602 0776 (Commercial Healthcare)

Tel: +44 (0) 800 121 4524 (New Therapies)

Email: healthuk@airproducts.com

Website: www.airproducts.co.uk/homecare/

The Association of Chartered Physiotherapists in Respiratory Care (ACPRC) **Stand number c57**

The Association of Chartered Physiotherapists in Respiratory Care (ACPRC) is a national body of physiotherapists interested in all fields of respiratory care. There are four key areas of representation: chronic diseases, critical care, cardiothoracics/surgery and paediatrics. With over 600 members it is one of the larger clinical interest groups within the Chartered Society of Physiotherapy. The ACPRC aims:

- to improve the exchange of ideas amongst those in respiratory physiotherapy
- to improve post registration education in the field of respiratory care
- to encourage the exchange of ideas between members through publications: journal/newsletters
- to compile a register of members and to establish a bureau to which members may apply for advice and help in respiratory care
- to encourage research in respiratory care and to provide a platform for discussion of ideas and "in progress" research

f) to promote contact with similar organisations in the UK and abroad.

Email: publicrelations@acprc.org

Website: www.acprc.org

The Association of Respiratory Nurse Specialists (ARNS) – *Leading, Inspiring and Empowering* **Stand number c51**

The Association of Respiratory Nurse Specialists (ARNS) exists to promote a higher level of respiratory nursing practice through leadership, education and professional development and to influence the direction of respiratory nursing care. As a major representative of respiratory nursing, ARNS seeks to proactively collaborate with other respiratory care organisations and relevant government and NHS initiatives in order to influence policy and developments for respiratory services as well as to promote the raising of standards and clinical effectiveness of respiratory care. Via its bespoke courses, study days and conferences, ARNS aims to support its members to deliver evidence based practice within the rapidly changing health-care environment. Via its web site and other means of communication, ARNS provides a supportive network for its members and encourages information sharing, best practice and research collaboration.

Tel: +44 (0) 207 269 5793

Email: info@arns.co.uk

Website: www.arns.co.uk

The Association for Respiratory Technology and Physiology (ARTP) **Stand number c59**

The ARTP is the sole professional organisation in the UK representing practitioners working in clinical respiratory physiology. We provide training courses in respiratory function measurement/interpretation and sleep physiology and provide the only national, professionally recognised qualifications in pulmonary function testing, spirometry and capillary blood gas sampling. Our Annual Conference is packed with exciting topics, featuring internationally renowned speakers.

The ARTP produces handbooks in spirometry and lung function testing. We are also involved in writing guidelines, standards and position statements.

2009–10 is an exciting year for ARTP. We will be launching our e-learning module in spirometry and launching ARTP *Sleep*, representing practitioners involved in Sleep Medicine.

Tel: +44 (0) 845 226 3068

Email: admin@artp.org.uk

Website: www.artp.org.uk

AstraZeneca **Stand numbers 11, 12 & 13**

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies, investing \$5.2 billion in medicines research and development in 2008, and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines.

Tel: +44 (0) 1582 836 000

Website: www.AstraZeneca.co.uk

EXHIBITORS' INFORMATION

Blackwell

Stand 63

Blackwell has been supplying specialist publications and academic books for over 125 years. With 50 shops around the UK, two dedicated medical bookshops and medical departments in all of our major outlets, Blackwell is the largest medical book supplier and retailer in the UK. We provide a specialist service to everyone in the medical profession, offering a wide range of books, e-books, and medical instruments. We are a contracted supplier to the NHS and the Department of Health.

Tel: +44 (0) 207 611 2160

Website: www.blackwell.co.uk

BOC Healthcare

Stand number 7

BOC Healthcare is a leading supplier of medical gases globally and in the UK. Our home oxygen service provides the best oxygen therapy and full support for patients of all ages with a wide variety of breathing problems. We currently supply oxygen therapy to approximately 10,000 patients living in the East of England.

In addition, our business development teams are currently looking into other services and products that we can offer to patients to enhance their lives. To find out more please visit stand 7.

Tel: +44 (0) 800 136 603

Email: healthcare.home-uk@boc.co.uk

Website: www.bochealthcare.co.uk

Boehringer Ingelheim/Pfizer

Stand numbers 6 & 9

Boehringer Ingelheim and Pfizer are committed to fighting chronic obstructive pulmonary disease (COPD) together. We aim to improve recognition and management of COPD, which can make a real difference to the quality of life of patients. Visit our stand to find out more.

Tel: +44 (0) 845 6022 3809

Email: medinfo@bra.boehringer-ingelheim.com

Website: www.boehringer-ingelheim.com

The British Lung Foundation

Stand number c62

The British Lung Foundation (BLF) is the only UK charity working for everyone affected by lung disease, including the health professionals who look after them. The charity provides a wide range of patient health information, a Helpline service, and direct support through Breathe Easy, BLF Nurses and the BLF Active exercise programme. It also works for positive change in the respiratory field by campaigning, lobbying, and raising funds for research. Stop by our stand to collect a sample copy of the BLF's new COPD Self Management Plan and Exercise Diary.

Tel: +44 (0)8458 50 50 20

Email: enquiries@blf-uk.org

Website: www.lunguk.org

CareFusion Portable Diagnostics

Stand number 28

CareFusion Portable Diagnostics (formally Micro Medical) will be exhibiting the MicroLoop, MicroLab and SpiroUSB Spirometers. Also on display will be the PulmoLife, a low cost COPD screening aid, together with a full range of pocket Spirometers, and breath Carbon Monoxide detection monitors, invaluable in smoking cessation programmes, including the NEW Baby CO for smoking cessation during pregnancy.

Tel: +44 (0) 1256 388 550

Email: micro.uksales@carefusion.com

Website: www.carefusion.com

Cellestis

Stand number 33

QuantiFERON®-TB Gold In-Tube (QFT™) is a blood test that measures the cell-mediated immune response of tuberculosis (TB) infected individuals. Approved by the FDA and CE marked, QFT is a modern replacement to the 100+ year-old tuberculin skin test (TST). QFT, like the TST, can be used as an aid in the diagnosis of latent tuberculosis infection and TB disease.

Tel: +49 (0) 6151 428 590

Email: Europe@cellestis.com

Website: www.cellestis.com

Chiesi Ltd

Stand numbers 29, 30, 37 & 38

A research-focused international company, developing and bringing innovative pharmaceutical solutions, which relieve and improve the quality of human life. An organisation that combines commitment and results with integrity, operating in a socially and environmentally responsible manner. Established in the areas of respiratory, cardiovascular and musculoskeletal medicine, with a research pipeline focused on the treatment of respiratory disease and rare illnesses.

Tel: +44 (0) 161 488 5555

Email: info@chiesi.uk.com

Website: www.chiesi.uk.com

DeVilbiss Healthcare

Stand number 40

The origins of DeVilbiss Healthcare date back to 1888 when Dr Allen DeVilbiss developed the first atomiser to replace the throat swab. Although our product portfolio may have changed somewhat, we have continued in the tradition of innovation and quality in the respiratory field. Our products are distributed in over 90 countries worldwide.

Today DeVilbiss Healthcare specialise in the manufacture and distribution of nebulisers, CPAP devices, oxygen therapy systems and the popular range of Minolta pulse oximeters.

Come and visit our stand to see our extended sleep therapy range and the iGo, a portable oxygen concentrator capable of delivering up to 3lpm constant flow and 6lpm pulsed flow oxygen.

Tel: +44 (0)1384 446858

Email: enquiries@devilbisshc.com

Website: www.devilbisshealthcare.com

Education for Health

Stand number c60

Education for Health is the largest international charity that trains health professionals to make a real difference to the lives of patients with long term conditions.

We provide professional health training across the fields of cardiovascular, respiratory and allergic disease, with the objective of transforming lives worldwide. Our educational programmes are run nationally and internationally and are accredited by the Open University.

Tel: +44 (0) 1926 836 840

Email: s.askew@educationforhealth.org

Website: www.educationforhealth.org

Fisher & Paykel Healthcare

Stand number 32

Fisher & Paykel Healthcare is the world leader in the design and manufacture of heated humidification devices used in respiratory care and in the treatment of obstructive sleep apnoea.

New technology means it is now possible to deliver high flows of medical air and/or oxygen directly to the patient's nose. Flows of

EXHIBITORS' INFORMATION

up to 50 L/min can be delivered nasally through the use of optimal humidity (37°C, 44mg/L). These flows allow accurate delivery of a prescribed fraction of inspired oxygen by meeting the patient's peak inspiratory demand. The unique wide bore Optiflow cannula was designed with comfort as a priority. Optimal humidification enables the high flow delivery while improving mucociliary clearance.

Tel: +44 (0) 1628 626 136

Email: customerservice@fphcare.co.uk

Website: www.fphcare.com

Forest Laboratories UK Ltd **Stand number 36**

Forest Laboratories UK Ltd, Forest Tosara Ltd and Forest Laboratories Ireland are the European subsidiaries of New York based Forest Laboratories Inc.

Sited in Dartford, Kent, Forest Laboratories UK Ltd is a specialist company with two main divisions; Prescription and Healthcare, each of which focuses on a small number of therapy areas.

The Prescription division specialises in cystic fibrosis, gastroenterology and dermatology therapies. The leading product within this division is Colomycin – an antibiotic used in the treatment of pseudomonal infections associated with cystic fibrosis.

Tel: +44 (0) 1322 421 800

Website: www.forestlabs.com

Genzyme **Stand number 31**

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Genzyme in the UK is a fully integrated business with manufacturing, research and commercial capabilities. Based in Cambridge MA, the company is focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues with a development programme concentrated on these fields, alongside other areas of unmet medical needs.

Tel: +44 (0) 1865 405 200

Website: www.genzyme.co.uk

GlaxoSmithKline UK Ltd/Allen & Hanburys **Stand numbers 16, 17, 24 & 25**

We have a challenging and inspiring mission: to improve the quality of human life by enabling people to do more, feel better and live longer. This mission gives us the purpose to develop innovative medicines and products that help millions of people around the world.

Tel: +44 (0) 208 990 9000

Website: www.allenandhanburys.co.uk and www.gsk.com

Hitachi Medical Systems **Stand number 27**

Hitachi Medical Systems – HI-VISION Endobronchial Ultrasound: Hitachi's new Endobronchial Ultrasound System (EBUS) combines high definition video imaging with high resolution ultrasound in complete synergy. This integrated solution offers a minimally invasive and less expensive alternative to mediastinoscopy – a safe and accurate approach for complete mediastinal staging. HI-VISION imaging for when 'tissue is the issue'.

Tel: +44 (0) 844 800 4294

Website: www.hitachi-medical-systems.com

Merck Sharp & Dohme Ltd **Stand number 21**

Merck Sharp & Dohme Limited is the UK subsidiary of one of the world's leading research-based pharmaceutical companies, Merck & Co, Inc, of Whitehouse St, NJ, USA. The company discovers, manufactures and markets a broad range of innovative products and services to improve human health.

Tel: +44 (0) 1992 467 272

Website: www.msd-uk.co.uk

The National Council for Palliative Care (NCPC) **Stand number c61**

The National Council for Palliative Care (NCPC) is the umbrella organisation for all those who are involved in providing, commissioning and using palliative care and hospice services in England, Wales and Northern Ireland. NCPC promotes the extension and improvement of palliative care services for all people with life-threatening and life-limiting conditions. NCPC promotes palliative care in health and social care settings across all sectors to government, national and local policy makers.

Tel: +44 (0) 20 7697 1520

Email: enquiries@ncpc.org.uk

Website: www.ncpc.org.uk

NHS Improvement **Stand number c55**

NHS Improvement is currently working with over 270 sites across England, with a focus on quality, productivity and innovation, NHS Improvement works closely with Trusts, clinical networks and the Department of Health to transform, deliver and build sustainable improvements across the entire pathway of care in cancer, diagnostics, heart, lung and stroke services. With nearly ten years practical service improvement experience, NHS Improvement aims to develop sustainable effective pathways and systems to improve the efficiency and quality of NHS services.

NHS Improvement has recently established a new Lung Improvement programme which will initially focus on Chronic Obstructive Pulmonary Disease.

Tel: +44 (0) 116 222 5113

Email: info@improvement.nhs.uk

Website: www.improvement.nhs.uk

Nutricia UK **Stand number 43**

Nutricia specialises in the delivery of advanced medical nutrition for the very young, the old and the sick. As well as being the largest specialist nutrition company in Europe, Nutricia is the market leader in the UK.

We supply high quality feeds, systems and support services to patients and health care professionals. Through our Nutricia Homeward service, we deliver nutritional feeds, enteral feeding systems and nursing care directly to patients' homes.

One of Nutricia's latest innovations is a disease targeted nutritional supplement which has been shown to enhance physical capacity when combined with exercise in COPD patients.

Email: resourcecentre@nutricia.co.uk

Website: www.nutricia.co.uk

Nycomed **Stand numbers 18, 19, 20, 22 & 23**

Nycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain,

EXHIBITORS' INFORMATION

osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.

Our mission is to provide medicines that make a real difference to patients and healthcare providers.

Our vision is to become the preferred pharmaceutical company by being responsive, reliable and focused on results.

Tel: + 44 (0) 1628 646 400

Email: nycomed.uk@nycomed.com

Website: www.nycomed.co.uk

Olympus KeyMed

Stand number 14

A wholly-owned subsidiary of the Olympus Corporation of Japan, Olympus KeyMed is an important part of the global Olympus network, with specific responsibility for the development and manufacture of medical equipment and industrial products for distribution worldwide. During the BTS Winter Meeting, Olympus KeyMed will be featuring the latest products in its respiratory portfolio on its stand, including the exciting Endobronchial Ultrasound range as well the IBV Valve System, a new minimally invasive treatment for diseased (for example, emphysema) or damaged (for example, air leaks) lung.

Tel: +44 (0)1702 616 333

Website: www.olympus.co.uk

Oxford Immunotec

Stand number 8

On stand number 8, Oxford Immunotec will be presenting the in vitro T-SPOT[®].TB assay for active and latent tuberculosis. It is extremely sensitive making it particularly suitable for immunosuppressed populations and all forms of extrapulmonary TB. It is very specific with no cross-reactivity to BCG vaccination or *M. avium*.

The T-SPOT[®].TB assay can identify TB contacts, and those who are regularly screened, including healthcare workers, HIV patients, cancer, transplant and immunosuppressed patients, including anti-TNF alpha therapies, immigrants and prisoners.

Tel: +44 (0) 1235 442 780

Email: info@oxfordimmunotec.com

Website: www.oxfordimmunotec.com

The PCD Family Support Group

Stand number c53

The PCD Family Support Group support adults and parents of children with primary ciliary dyskinesia (PCD). PCD is an inherited, relatively rare condition associated with an abnormality of cilia, which may affect the lungs, sinuses and ears.

The group was formed in 1991 to:

- Provide support to adults with PCD and parents of children known to have the condition
- Bring PCD to the attention of the medical profession and the public
- Provide an up to date information service

Tel: +44 (0) 1908 281 635

Email: chair@pcdsupport.org.uk

Website: www.pcdsupport.org.uk

Pentax Life Care

Stand number 41

With over 80 years experience of optical and technological innovation and a truly global presence, PENTAX LIFE CARE is internationally renowned for setting new standards in the world of endoscopy. With a wide range of specialist flexible

endoscopes, both video and fibre optic, that are specifically designed to meet the demands of today's clinicians for both therapeutic and diagnostic procedures. PENTAX LIFE CARE delivers comprehensive service and finance packages to suit individual customer needs. Endoscope repairs are performed by a UK based dedicated team of factory trained technicians providing an unrivalled level of customer service that can ensure high levels of repair quality, coupled with quick turnaround times. This is also supported by an extensive fleet of loan instruments to ensure all our customers can maintain their service. Following customer feedback on how we can improve our service further, we have now extended our team of field based technicians who provide onsite maintenance and support.

Tel: +44 (0) 1753 792 723

Email: lifecare.sales@pentax.co.uk

Website: www.pentax.co.uk

Pharmaxis

Stand number 26

Pharmaxis is a specialist pharmaceutical company committed to the research, development and commercialisation of human therapeutic products that address chronic respiratory and autoimmune diseases. Our R&D activity has resulted in the successful development of mannitol as a diagnostic test for bronchial hyperresponsiveness. An osmotic agent is also currently being researched as a therapeutic mucoactive agent.

Tel: + 44 (0)1582 434 240

Email: gill.rowe@pharmaxis.co.uk

Website: www.pharmaxis.com.au

Philips Respironics

Stand numbers 4 & 5

Philips Respironics, a global leader in the sleep and respiratory markets, is passionate about improving the quality of people's lives with solutions that are designed around the needs of our customers and their patients. For Philips Respironics, innovation is driven by gaining insight into the needs of the people who use our products in the areas of sleep management, oxygen therapy, non-invasive ventilation and respiratory drug delivery. This tradition of innovation combined with our ability to anticipate market needs has made Philips Respironics a name acknowledged worldwide as a pace-setter in the markets we serve.

Tel: +44 (0) 800 1300 845

Email: rukcustomerservices@respironics.com

Website: www.respironicsonline.co.uk

PROACT Medical

Stand number 45

PROACT Medical have been supplying high quality diagnostic equipment and airway management products to healthcare professionals since 1995. We believe in providing the highest quality equipment at wholesale prices, such as the world leading range of Nonin pulse oximetry. The Nonin range is the first choice for professionals – all purpose, reliable and accurate pulse oximetry, type tested and fully compliant to ISO:9919:2005. Also on show is Nonin nVision data analysis software along with Medair Capnography, Spirit stethoscopes and Trimline disposable and reusable NIBP cuffs. Contact our sales team for further information.

Tel: +44 (0)845 051 4244

Email: sales@proactmedical.co.uk

Website: www.proactmedical.co.uk

EXHIBITORS' INFORMATION

ProStrakan Group plc

Stand number 15

ProStrakan Group plc is a specialty pharmaceutical company engaged in the development and commercialisation of patient-friendly prescription medicines. The company's development facilities are situated in Galashiels in Scotland. EU-wide sales and marketing of ProStrakan's portfolio of products are handled by subsidiaries in the UK, US, France, Germany, Spain and other EU countries.

Tel: +44 (0) 1896 664 000

Website: www.prostrakan.com

The Pulmonary Hypertension Association UK

Stand number c56

The Pulmonary Hypertension Association UK (PHA-UK) is a national patient support charity that provides help, understanding and information for people whose lives are touched by this rare and devastating lung disease.

Tel: +44 (0) 1709 761 450

Email: office@pha-uk.com

Website: www.pha-uk.com

ResMed (UK) Ltd

Stand number 44

ResMed (UK) Ltd is a leading provider of cutting edge technology for the management of respiratory insufficiency and sleep disordered breathing. We would like to invite you to explore the capabilities of our equipment including ventilators and masks. Our machines are capable of bilevel, pressure and volume control, volume targeting and mouthpiece ventilation. Our mask portfolio includes non-vented and vented disposable and long term face masks.

Tel: +44 (0) 1235 862 997

Email: reception@resmed.co.uk

Website: www.resmed.com

Respiratory Education UK

Stand number c52

At Respiratory Education UK our fundamental goal is to promote excellence in respiratory care for patients and professionals.

This is achieved through a number of key objectives including the design and delivery of practical and academic study events; influencing respiratory practice via active research and promoting best practice through a number of respiratory related projects. COPD, Asthma, NIV, Spirometry, Commissioning and Consultation Skills are just some examples of the topics we cover, offering a number of named awards at diploma, degree and masters level. These are attainable within as little as one year.

We look forward to continuing to contribute towards the ongoing advancements in respiratory care through aiding the development of healthcare professionals across the country.

To find out more please visit us at:

Tel: +44 (0) 151 529 2598

Email: info@respiratoryeduc.com

Website: www.respiratoryeduc.com

Rocket Medical

Stand number 3

Rocket Medical, a privately owned UK manufacturer of disposable medical devices, are pleased to be supporting the BTS at the Winter Meeting again this year. Please come and visit us on stand number 3 where we can demonstrate our newly launched

SELDINGER Insertion Trays with safety dilators and new improved guide wires and feeders. Alongside this are the many other well known devices Rocket have designed and manufactured thanks to the feedback and support of the many BTS members. A truly interactive and hands on stand!

Tel: +44 (0) 7971 541 316

Email: beverley@rocketmedical.com

Website: www.rocketmedical.com

Sleep Apnoea Trust

Stand number c54

Sleep Apnoea Trust is a charitable patient support group, which for the past sixteen years has supported sleep apnoea sufferers, their partners and families, throughout England and Wales. The Trust provides assistance by means of:

- A patient association (SATA) whose members provide mutual support to each other
- A website, which contains general information about sleep apnoea, together with details of sleep clinics which specialise in the condition
- *Sleep Matters* a newsletter published at regular intervals
- A series of information leaflets, which are sent to all sleep clinics in England and Wales
- Telephone help lines
- An annual conference
- The provision of medical alert cards
- A campaign for the better provision of services by the NHS

Tel: +44 (0) 845 60 60 685

Email: sata.admin@tiscali.co.uk

Website: www.sleep-apnoea-trust.org

Teva UK Ltd

Stand numbers 34 & 35

Teva UK Limited is the world's largest generics company, with visibility in three UK marketplaces: Generics, Hospitals and Brands. Teva Brands manage the respiratory portfolio, including innovative formulations such as Qvar, the inhaled corticosteroid with smaller particles; innovative delivery devices such as the award winning Easi-Breathe® inhaler. Teva Brands also promote Mucodyne™, a mucolytic agent for COPD patients who suffer with excess mucus.

Tel: +44 (0) 20 7540 7000

Website: www.tevauk.com

Thorax (BMJ Group)

Stand number c58

Thorax, the highest ranked European journal, is published by the BMJ Group. Covering all aspects of pulmonary medicine, *Thorax* provides coverage of recent developments in basic biomedical sciences and publishes a regular review series to keep you abreast of advances. *Thorax* is essential reading for those involved in thoracic or respiratory disciplines.

Thorax is the official journal of the British Thoracic Society and has an increasing impact factor, currently 7.069. For a sample copy, subscription details, an online demonstration or more information about our online legacy archive, visit our stand at the BTS Winter Meeting.

Tel: +44 (0)20 7387 4499

Email: support@bmjgroup.com

Website: www.thorax.bmj.com

EXHIBITORS' INFORMATION

UK Medical

Stand number 42

UK Medical is the official UK distributor of the PleurX catheter for home management of recurrent malignant pleural effusion and ascites. PleurX is an excellent option for patients with trapped lung and those that have failed talc pleurodesis. However, recent clinical data has led to an opening in its indication, with strong justification for its use in patients who would normally be considered candidates for talc slurry or thoracoscopic talc insufflation.

With UK Medical's commitment to providing the highest level of training and support and over 30 published clinical papers supporting its use, PleurX is an evidence-based option that you can offer your patients with confidence.

Tel: +44 (0) 114 268 8880

Email: info@ukmedical.com

Website: www.ukmedical.com

Vitalograph

Stand number 1

Vitalograph is a world leading provider of outstanding quality respiratory diagnostic devices, clinical trials and medical equipment servicing. Our extensive respiratory range includes spirometers, peak flow meters, COPD screeners, asthma monitors, e-diaries, inhaler trainers and resuscitation devices.

With a pioneering heritage of excellence spanning half a century, Vitalograph continue to make valuable contributions to effective medical care and enhanced quality of life.

Tel : +44 (0) 1280 827 110

Email: sales@vitalograph.co.uk

Website: www.vitalograph.co.uk